A genome wide scan for familial high myopia suggests a novel locus on chromosome 7q36

L Naiglin, C Gazagne, F Dallongeville, C Thalamas, A Idder, O Rascol, F Malecaze, P Calvas

High myopia often appears as a familial disease. It is usually defined as a refraction error equal to or below −6 dioptries (D) in each eye. Highly myopic patients represent 27−33% of the myopic population.1 The prevalence of the disease in the general population varies according to the country, from 2.1% in the USA,2 to 3.2% in France,3 and up to 9.6% in Spain.4 High myopia is also termed “pathological” myopia because of its potential complications. The highly myopic eye is usually characterised by an abnormal lengthening and a posterior staphyloma. It is often accompanied by glaucoma, cataracts, macular degeneration, and retinal detachment, leading to blindness when the damage to the retina is extremely severe.

Both genetic and environmental factors, such as close work, are known to play a role in the aetiology of high myopia. The inheritance of the disease is equivocal. Several genealogical studies have shown autosomal dominant or autosomal recessive modes of inheritance.4−11 Rare cases of sex linked transmission have been observed.12

In a previous study,7 we showed that, assuming a single gene model, autosomal dominant transmission with weak penetrance was largely present in the families that we studied. Young et al have recently reported linkage of familial high myopia to chromosome regions 18p and 12q.8 We previously found no evidence for linkage to the former chromosomal region in the families of our study. Several putative candidate loci were excluded as well in these families, such as the locus for Stickler syndrome types 1 and 2, versican and aggregan genes, Marfan 1 syndrome, and a Marfan-like disorder localised to 3p24.2−p25.

In order to find new loci implicated in high myopia, we conducted a genome screen in 23 families following an autosomal dominant mode of inheritance with weak penetration. Here, we provide further evidence for genetic heterogeneity by excluding the chromosome 12q and 18p regions, previously linked to familial high myopia,12 and report suggestive evidence for the presence of a third autosomal locus on chromosome 7q.

SUBJECTS, MATERIALS, AND METHODS

Subjects
Medical history and ophthalmic assessment were obtained from 140 participants from 21 French families and two Algerian families, after informed consent according to French law. We focused our study on isolated bilateral high myopia. Families with unilateral high myopia, syndromes with high myopia, and myopia of prematurity were excluded.

For each patient, subjective refraction and keratometry were performed. Axial lengths were also measured for almost all of the subjects. Objective refraction was measured by automatic refractometry. The refraction defect in spherical equivalent was the criterion chosen to classify subjects into two groups, high myopes and unaffected persons. A subject was considered to be highly myopic if the refraction error in the lesser affected eye was −6 D or below. We considered low myopes (myopia between −6 and −1 D), emmetropes (refraction status between −1 and 1 D), and patients with hyperopia (refraction status greater than 1 D) as unaffected subjects. Details of refractive status are summarised in table 1.

DNA analysis/marker typing
Venous blood samples were collected in EDTA for DNA extraction according to standard methods.13 The genome screen used 400 highly polymorphic fluorescently labelled microsatellite markers, with an average spacing of 10 cM, from the ABI PRISM Linkage Mapping Set MD-10 (Perkin-Elmer, Warrington, UK). The map positions were generated from the CEPH genotype data used for the Généthon map. For fine mapping, we selected those regions with a two point lod score >1. This is clearly well below the threshold for statistical significance but provided a convenient cut off for identification of regions meriting higher density genotyping. Additional polymorphic markers (heterozygosity ≥75%) were selected from the Généthon and the CHLC genetic maps and were fluorescently labelled. All labels were either 6-FAM, HEX, or NED 5’ end labels.

All PCR reactions were carried out using 25 ng of genomic DNA as a template in a mixture of 1 × Perkin-Elmer PCR buffer, 2.5 mmol/l MgCl2, 200 nmol/l of each dNTP, 5 pmol of each primer, and 0.1 μl of TaqGold polymerase (Perkin-Elmer, Warrington, UK) in a final volume of 15 μl. The thermocycling conditions were 95°C for 18 minutes, followed by 38 cycles at 94°C for one second, 55°C for 25 seconds, and 72°C for five seconds, followed by a 10 minute final extension step at 72°C. PCR products were pooled with regard to their size range and labelling, mixed with a formamide sample buffer, and electrophoresed through preheated 6% acrylamide/50% (W/V) urea gels on an ABI 373 DNA sequencer XL upgrade (PE Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s recommendations. All amplimers were sized by the Genescan Analysis 3.1 software (PE Applied Biosystems, Foster City, CA, USA) and scored by the Genotyper 2.1 software (PE Applied Biosystems, Foster City, CA, USA) with respect to the CEPH control genotype No 1347-02.
Table 1  Refraction status of the patients

<table>
<thead>
<tr>
<th>Family</th>
<th>Patient</th>
<th>Sex</th>
<th>Right eye (D)</th>
<th>Left eye (D)</th>
<th>Phenotype</th>
<th>Age at examination (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6</td>
<td>F</td>
<td>Blind*</td>
<td>Blind*</td>
<td>A</td>
<td>81</td>
</tr>
<tr>
<td>1</td>
<td>7</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
</tr>
<tr>
<td>1</td>
<td>8</td>
<td>F</td>
<td>−6.25</td>
<td>−8.5</td>
<td>A</td>
<td>42</td>
</tr>
<tr>
<td>1</td>
<td>9</td>
<td>M</td>
<td>−2</td>
<td>−1.5</td>
<td>U</td>
<td>7</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>9</td>
</tr>
<tr>
<td>1</td>
<td>11</td>
<td>M</td>
<td>−2.75</td>
<td>−1.25</td>
<td>U</td>
<td>39</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>73</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>F</td>
<td>2</td>
<td>1.5</td>
<td>U</td>
<td>71</td>
</tr>
<tr>
<td>2</td>
<td>7</td>
<td>M</td>
<td>0.75</td>
<td>0.5</td>
<td>U</td>
<td>45</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>F</td>
<td>−20</td>
<td>−13</td>
<td>A</td>
<td>44</td>
</tr>
<tr>
<td>2</td>
<td>9</td>
<td>M</td>
<td>0.5</td>
<td>−1</td>
<td>U</td>
<td>52</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>23</td>
</tr>
<tr>
<td>2</td>
<td>11</td>
<td>F</td>
<td>0.5</td>
<td>0.5</td>
<td>U</td>
<td>19</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>M</td>
<td>2</td>
<td>1.75</td>
<td>U</td>
<td>58</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>F</td>
<td>−11.5</td>
<td>−11.5</td>
<td>A</td>
<td>57</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>M</td>
<td>−5.5</td>
<td>−9.5</td>
<td>U</td>
<td>60</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>7</td>
<td>M</td>
<td>−16.5</td>
<td>−16.5</td>
<td>A</td>
<td>28</td>
</tr>
<tr>
<td>3</td>
<td>11</td>
<td>M</td>
<td>−0.25</td>
<td>−0.25</td>
<td>U</td>
<td>32</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>F</td>
<td>−2.75</td>
<td>−4</td>
<td>U</td>
<td>70</td>
</tr>
<tr>
<td>4</td>
<td>7</td>
<td>M</td>
<td>Blind*</td>
<td>−24.5</td>
<td>A</td>
<td>40</td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>M</td>
<td>−3.75</td>
<td>−0.25</td>
<td>U</td>
<td>38</td>
</tr>
<tr>
<td>4</td>
<td>9</td>
<td>M</td>
<td>−4</td>
<td>−3</td>
<td>U</td>
<td>35</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
<td>F</td>
<td>−13.75</td>
<td>−14.25</td>
<td>A</td>
<td>63</td>
</tr>
<tr>
<td>5</td>
<td>7</td>
<td>M</td>
<td>0</td>
<td>0.25</td>
<td>U</td>
<td>38</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>F</td>
<td>0.5</td>
<td>0</td>
<td>U</td>
<td>36</td>
</tr>
<tr>
<td>5</td>
<td>9</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>33</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>M</td>
<td>−14</td>
<td>−16</td>
<td>A</td>
<td>30</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>F</td>
<td>−10</td>
<td>−6.75</td>
<td>A</td>
<td>60</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>M</td>
<td>−0.5</td>
<td>−0.75</td>
<td>U</td>
<td>35</td>
</tr>
<tr>
<td>6</td>
<td>8</td>
<td>F</td>
<td>−14</td>
<td>−21</td>
<td>A</td>
<td>33</td>
</tr>
<tr>
<td>6</td>
<td>9</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>10</td>
<td>M</td>
<td>−6</td>
<td>−13</td>
<td>A</td>
<td>7</td>
</tr>
<tr>
<td>7</td>
<td>3</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>68</td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>F</td>
<td>−18</td>
<td>−18</td>
<td>A</td>
<td>66</td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>62</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>F</td>
<td>−6.5</td>
<td>−6.75</td>
<td>A</td>
<td>61</td>
</tr>
<tr>
<td>7</td>
<td>8</td>
<td>M</td>
<td>−5.75</td>
<td>−4.25</td>
<td>U</td>
<td>41</td>
</tr>
<tr>
<td>7</td>
<td>9</td>
<td>F</td>
<td>−7</td>
<td>−7</td>
<td>A</td>
<td>39</td>
</tr>
<tr>
<td>7</td>
<td>10</td>
<td>M</td>
<td>−2</td>
<td>−1.75</td>
<td>U</td>
<td>39</td>
</tr>
<tr>
<td>7</td>
<td>11</td>
<td>F</td>
<td>−0.5</td>
<td>0</td>
<td>U</td>
<td>38</td>
</tr>
<tr>
<td>7</td>
<td>12</td>
<td>F</td>
<td>−7</td>
<td>−7</td>
<td>A</td>
<td>28</td>
</tr>
<tr>
<td>7</td>
<td>13</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>14</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>15</td>
<td>M</td>
<td>−4.25</td>
<td>−4.25</td>
<td>U</td>
<td>12</td>
</tr>
<tr>
<td>7</td>
<td>16</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>F</td>
<td>−0.5</td>
<td>0</td>
<td>U</td>
<td>81</td>
</tr>
<tr>
<td>8</td>
<td>6</td>
<td>F</td>
<td>−4.5</td>
<td>−3.5</td>
<td>U</td>
<td>80</td>
</tr>
<tr>
<td>8</td>
<td>7</td>
<td>M</td>
<td>−15</td>
<td>−14</td>
<td>A</td>
<td>49</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>47</td>
</tr>
<tr>
<td>8</td>
<td>9</td>
<td>M</td>
<td>−12</td>
<td>−10</td>
<td>A</td>
<td>47</td>
</tr>
<tr>
<td>8</td>
<td>10</td>
<td>M</td>
<td>−6.5</td>
<td>−5</td>
<td>U</td>
<td>24</td>
</tr>
<tr>
<td>8</td>
<td>11</td>
<td>M</td>
<td>−10</td>
<td>−9</td>
<td>A</td>
<td>22</td>
</tr>
<tr>
<td>9</td>
<td>3</td>
<td>F</td>
<td>−12</td>
<td>−12</td>
<td>A</td>
<td>67</td>
</tr>
<tr>
<td>9</td>
<td>5</td>
<td>F</td>
<td>−14</td>
<td>−20</td>
<td>A</td>
<td>62</td>
</tr>
<tr>
<td>9</td>
<td>6</td>
<td>F</td>
<td>−6</td>
<td>−4.75</td>
<td>U</td>
<td>26</td>
</tr>
<tr>
<td>9</td>
<td>10</td>
<td>M</td>
<td>−8.5</td>
<td>−8.5</td>
<td>A</td>
<td>44</td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td>F</td>
<td>−6.5</td>
<td>−4.5</td>
<td>U</td>
<td>16</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>M</td>
<td>−2</td>
<td>−1.25</td>
<td>U</td>
<td>12</td>
</tr>
<tr>
<td>10</td>
<td>9</td>
<td>F</td>
<td>−1.25</td>
<td>−1</td>
<td>U</td>
<td>9</td>
</tr>
<tr>
<td>11</td>
<td>5</td>
<td>F</td>
<td>−12</td>
<td>−17</td>
<td>A</td>
<td>77</td>
</tr>
<tr>
<td>11</td>
<td>7</td>
<td>F</td>
<td>−15.5</td>
<td>−20</td>
<td>A</td>
<td>56</td>
</tr>
<tr>
<td>11</td>
<td>8</td>
<td>M</td>
<td>−1</td>
<td>−0.5</td>
<td>U</td>
<td>50</td>
</tr>
<tr>
<td>11</td>
<td>9</td>
<td>F</td>
<td>−4.5</td>
<td>−3</td>
<td>U</td>
<td>39</td>
</tr>
<tr>
<td>12</td>
<td>5</td>
<td>M</td>
<td>4</td>
<td>4</td>
<td>U</td>
<td>76</td>
</tr>
<tr>
<td>12</td>
<td>6</td>
<td>M</td>
<td>2</td>
<td>2.5</td>
<td>U</td>
<td>73</td>
</tr>
<tr>
<td>12</td>
<td>7</td>
<td>M</td>
<td>−16</td>
<td>−16</td>
<td>A</td>
<td>47</td>
</tr>
<tr>
<td>12</td>
<td>8</td>
<td>F</td>
<td>−4.75</td>
<td>−5.5</td>
<td>U</td>
<td>53</td>
</tr>
<tr>
<td>12</td>
<td>9</td>
<td>M</td>
<td>−14</td>
<td>−14</td>
<td>A</td>
<td>45</td>
</tr>
<tr>
<td>12</td>
<td>10</td>
<td>F</td>
<td>−1</td>
<td>−1.5</td>
<td>U</td>
<td>47</td>
</tr>
<tr>
<td>12</td>
<td>11</td>
<td>M</td>
<td>2</td>
<td>2.5</td>
<td>U</td>
<td>44</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>M</td>
<td>−2.25</td>
<td>−2.75</td>
<td>U</td>
<td>22</td>
</tr>
<tr>
<td>12</td>
<td>13</td>
<td>M</td>
<td>−3.5</td>
<td>−3.5</td>
<td>U</td>
<td>16</td>
</tr>
<tr>
<td>12</td>
<td>14</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>18</td>
</tr>
<tr>
<td>12</td>
<td>15</td>
<td>F</td>
<td>−3</td>
<td>−4.5</td>
<td>U</td>
<td>17</td>
</tr>
<tr>
<td>12</td>
<td>16</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>11</td>
</tr>
<tr>
<td>13</td>
<td>5</td>
<td>M</td>
<td>−19</td>
<td>−17.5</td>
<td>A</td>
<td>68</td>
</tr>
<tr>
<td>13</td>
<td>6</td>
<td>F</td>
<td>−0.5</td>
<td>0</td>
<td>U</td>
<td>66</td>
</tr>
<tr>
<td>13</td>
<td>7</td>
<td>M</td>
<td>−4.75</td>
<td>−5.75</td>
<td>U</td>
<td>41</td>
</tr>
</tbody>
</table>

continued
Statistical analysis
In parametric statistics, we assumed an autosomal dominant mode of inheritance with 58.4% penetrance and a myopia gene frequency of 0.013, as they were established in a previous study. Data were simulated using the program SLINK\textsuperscript{11} in order to determine the power to detect linkage. Two point lod scores and maximum lod scores (Zmax) were calculated using the MLINK and ILINK routines of the FASTLINK program\textsuperscript{12} and genetic heterogeneity was tested using the HOMOG program. Marker allele frequencies were estimated from the non-inbred founders in the data. The two Algerian pedigrees were included in the whole population to calculate a unique set of allele frequencies.

Multipoint lod score analysis of the genome screen was performed with the GENEHUNTER computer package\textsuperscript{13} under the parametric model previously defined (lod) and the non-parametric option. In addition, lod scores were calculated under the locus heterogeneity hypothesis (hlod). The proportion of the families linked (alpha) was allowed to vary until the hlod was maximised. Map order and genetic distances between markers were determined from the Généthon Human Linkage Map.\textsuperscript{14}

Table 1 continued

<table>
<thead>
<tr>
<th>Family</th>
<th>Pedigree</th>
<th>Refractive Error</th>
<th>Sex</th>
<th>Status</th>
<th>Age</th>
<th>Gender</th>
<th>Location</th>
<th>LOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>M</td>
<td>-6.5</td>
<td>7</td>
<td>A</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>-8.5</td>
<td>7</td>
<td>U</td>
<td>42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>-5.25</td>
<td>7</td>
<td>U</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>-4.5</td>
<td>7</td>
<td>U</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>-3.5</td>
<td>7</td>
<td>U</td>
<td>50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>M</td>
<td>0</td>
<td>0</td>
<td>U</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{*}Blind: the refractive error is not known but the person is blind in the indicated eye because of retinal detachment owing to high myopia.

\textsuperscript{†}This person was considered highly myopic because a retinal detachment leading to blindness occurred since the examination.

D, diopter; NA, not available; A, affected; U, unaffected.

www.jmedgenet.com
RESULTS
Twenty-three families were included in the genome scan (fig 1). They were not selected a priori, in order to avoid a bias in favour of dominance. They only had to have at least one highly myopic subject in their pedigree. Fifty highly myopic patients with a sex ratio of 1 were studied. The mean refraction value was $-13.05$ (SD 4.92) D for high myopes versus $-1.32$ (SD 2.43) D for non-highly myopic subjects. The mean axial lengths were 27.87 (SD 2.92) mm and 23.52 (SD 1.26) mm for highly myopic and non-highly myopic subjects, respectively.

Figure 1  Pedigrees of the 23 families studied with familial high myopia. Filled symbols denote affected subjects (myopia $< -6$ D).
and analysed by two point and multipoint linkage analysis. The new markers for chromosome 4q, 5p, 13q, and 15q gave similar or lower two point lod scores. The multipoint analysis confirmed the exclusion of these regions (fig 3). In contrast, the maximum two point lod score with chromosome 7q markers reached 1.87 at $\theta = 0$ (table 2). The multipoint analysis showed suggestive evidence of linkage with a maximum multipoint lod score of 2.81 (fig 3), whereas no locus heterogeneity could be detected. The implicated region extended from D7S798 to D7S2423, the latter marker being located in the immediate vicinity of the telomere. A recombination event between D7S798 and D7S2546 in family 17 (fig 4) allowed us to set this interval in an 11.7 cM region extending from D7S798 to the telomeric end of the chromosome.

**DISCUSSION**

In our previous study, we have shown that genetic factors were of decisive importance in the aetiology of familial high myopia. By segregation analysis, we showed that an autosomal dominant mode of inheritance with weak penetrance was largely favoured in the families that we studied. Nevertheless, some families (family 2) showed an autosomal recessive mode of transmission. The weak penetrance of a dominant allele may give the appearance of recessive transmission which could not be totally excluded in some families.

The pathophysiology of isolated high myopia remains unknown. Besides heredity, the trait depends on environmental factors and, moreover, the genetic component is also complex. Indeed, we found that the locus for familial high myopia on chromosome 18p11.31, recently reported by Young et al., was probably not implicated in our families. This indicates that the disease is genetically heterogeneous as there were no obvious phenotypic differences between our patients and the ones reported by these authors.

We now confirm the locus heterogeneity of the disease with the families we have studied by excluding the loci for familial high myopia on chromosomes 12q21-23 and 18p11.31. Moreover, the results obtained during our genome scan suggest the presence of a new susceptibility locus for familial high myopia on chromosome 7q36 within a 11.7 cM interval. Evidence for locus heterogeneity could not be detected, even if some families, when the data were examined in detail, did not seem to be linked. The added high resolution markers were informative in our population and gave results in keeping with the simulation test, which predicted a power of only 41.6% to obtain a lod score above 3. Furthermore, the complexity of the high myopia trait probably leads to the decrease in the power to detect significant linkage.

The non-parametric lod score curve of the genome scan (data not shown) showed the same variations as the lod score curve but remained less powerful. This strongly suggested that our parametric segregation model was correct and that our results were not due to a possible error in the model.

Myopia is commonly considered as a complex, multifactorial trait, where several genes could act together in a quantitative way. To date, in single families or limited familial series,
single loci have been identified. Our data suggest that a new locus triggers or participates in familial high myopia. The computational search for genes and/or expressed sequence tags physically mapped between markers D7S798 and the telomere showed numerous unidentified transcripts, mRNAs for an open reading frame, and several genes. None of these appeared to be good candidate genes on the basis of their known function. In addition, there is no evidence of any closely related genes shared by the regions of interest on chromosomes 7q36, 12q21-23, and 18p11.31.

A majority of the families that we studied contained low myopic persons whom we considered as being unaffected, in order to preserve phenotypic homogeneity. The −6 diopter limit for high myopia that was chosen for the current clinical definition cannot be considered perfectly biologically accurate. Consequently, it would be interesting to analyse high myopia as a quantitative trait.

In summary, we provide suggestive evidence for the presence of a third autosomal locus for familial high myopia on chromosome 7q36. Studies are currently under way in our
laboratory, in order to validate these results and to reduce the critical region for high myopia. The recruitment and analysis of new families and/or new members of the families already studied are needed before starting gene isolation experiments. The characterisation of the genes implicated in this common eye disorder will lead to a better understanding of the molecular mechanisms contributing to eye shape and growth.

ACKNOWLEDGEMENTS

Electronic database information. URLs for data in this paper are as follows: Perkin-Elmer, http://www.pebio.com/ga/ (for ABI PRISM Linkage Mapping Set MD-10). Genethon, http://genethon.fr (for additional polymorphic markers). CHLC Genetic maps, http://chlc.org/ChlcMaps.html (for additional polymorphic markers). Human Gene Map ‘99, http://www.ncbi.nlm.nih.gov/genemap99 (for genes and expressed sequence tags in the region of interest within the interval between marker D7S798 and the telomere). We thank Dr L Cardon for his helpful discussion and for contributing actively to the statistical part of this work and Professor A Hovnanian for his critical review and comments on the manuscript. We also extend many thanks to the members of the myopia families. This work was supported by grants from the Association Retina France and from INSERM: Programme de Recherche en Santé No 4P01SD.

Authors’ affiliations

L Naiglin, P Calvas, Laboratoire d’Immuno-Génétique Moléculaire, Université Paul Sabatier, Hôpital Purpan, Place du Dr Baylac, 31059 Toulouse cedex, France

C Gazagne, F Malecaze, Clinique d’Ophtalmologie, CHU de Toulouse, Hôpital Purpan, Toulouse, France

F Dallongeville, P Calvas, Service de Génétique Médicale, Hôpital Purpan, Pavillon Lefèbvre, Toulouse, France

C Gazagne, F Malecaze, Laboratoire d’Ophtalmologie, Université Paul Sabatier, Toulouse, France

A Idder, INÉSSMO Clinique Ophtalmologique, EHS d’Oran, Algerie

F Malecaze, Laboratoire d’Ophtalmologie, Université Paul Sabatier, Hôpital Purpan, Place du Dr Baylac, 31059 Toulouse cedex, France; patrick.calvas@mipnet.fr

REFERENCES

Supportive evidence for the DYX3 dyslexia susceptibility gene in Canadian families

T L Petryshen, B J Kaplan, M L Hughes, J Tzenova, L L Field

A previous report in the Journal by Fagerheim et al identified a dyslexia locus (DYX3) on chromosome 2p15-p16 in a large Norwegian family with autosomal dominant inheritance of dyslexia. Parametric linkage analyses using three diagnostic schemes found significant evidence for linkage in this family (maximum lod = 4.3 at D2S378), which was supported by non-parametric linkage analysis (p=0.0009 between D2S2352 and D2S1337). Furthermore, identification of a three marker haplotype cosegregating with dyslexia in the family defined a 2 cM region between D2S2352 and D2S1337 that probably harbours the DYX3 gene. Replication of this linkage in other families would confirm the existence of the locus. We therefore examined our independent sample of dyslexia families and found preliminary evidence for linkage to the DYX3 locus. Here, we report the results of more comprehensive analyses, which provide further evidence for the chromosome 2p dyslexia locus.

METHODS

As described in detail elsewhere, our sample consists of 96 Canadian families (877 subjects), each containing two or more sibs diagnosed with phonological coding dyslexia (PCD). This diagnosis was used since the key problem in most reading disabled subjects is a specific difficulty in the phonological coding component of reading, where written words are sounded out using grapheme-phoneme (letter-sound) rules. The PCD diagnosis (affected, unaffected, or uncertain) was determined for all subjects primarily based on psychometric test results for phonological coding. Scores from the phonological and orthographic (recognition of letter patterns) coding, were used to assist in diagnosis, as was reading history for adults. The PCD phenotype was used for parametric and non-parametric linkage analyses. Scores from the phonological awareness, phonological coding, and spelling tests were used in quantitative trait variance component linkage analyses, after conversion to standard scores (for phonological coding and spelling) or age adjustment (for phonological awareness). Of the 96 families, 46 were nuclear families consisting of both parents, two or more affected children, and unaffected children if available, with an average family size of five members. The remaining 50 families were extended kindreds consisting of a nuclear family and other branches with affected and unaffected relatives, ranging in size from six to 107 members (average 18 members). Seven microsatellite markers spanning the DYX3 region were selected from the report of Fagerheim et al and automated genotyping was performed using a LI-COR 4200S-2 Gene ReadIR DNA Analyzer. Marker allele frequencies were calculated from the parents of one nuclear family per pedigree. The Genethon genetic map was used for intermarker order and distances: (pter) D2S1352 - 4 cM - D2S2352 - 1 cM - D2S378 - 0 cM - D2S2279 - 0 cM - D2S2183 - 1 cM - D2S1337 - 2 cM - D2S393 (cen). This marker order corresponded to the order from the human genome sequence.

Two point parametric linkage analysis was performed using FASTLINK (version 4.1P) from the LINKAGE programs, and multipoint parametric linkage analysis under genetic heterogeneity was performed using the GENEHUNTER program (version 2.0). Parametric analyses were performed under a dominant model with 1% disease allele frequency and penetrances of 0.04, 0.99, and 0.99 for aa, Aa, AA genotypes for males and 0.01, 0.85, 0.85 for females. These values were chosen to match those in the models used by Fagerheim et al. Multitpoin non-parametric linkage analysis (NPL) was performed using GENEHUNTER by analysing all affected family members. Multipoint variance component analysis was also performed using GENEHUNTER under four models that all included QTL additive variance, polygenic additive variance, and environmental variance, and with dominance variance at neither, both, or either the QTL or polygenes. Note that GENEHUNTER can only accommodate pedigrees of a limited size, so it was necessary to subdivide 10 large pedigrees, probably reducing the power to detect linkage. Marker haplotypes were constructed using GENEHUNTER to determine whether any families possessed the Norwegian cosegregating haplotype.

RESULTS

Results of two point and multipoint parametric linkage analyses provided weak evidence for linkage between PCD and the DYX3 region (maximum two point lod score = 0.77, θ=0.3 at D2S1352, multipoint peak lod = 0.07 at D2S1352). NPL analysis provided stronger evidence for linkage to DYX3, with a peak NPL Z_all score of 2.33 (p=0.0087) at D2S1352, and p<0.05 from D2S1352 to D2S2352, thus surpassing the recommended p=0.01 required to claim significant evidence for linkage in a replication study. The discrepancy between the parametric and NPL results suggested that our parametric analysis model (based on that of Fagerheim et al) may not have been the most appropriate for our Canadian sample. We therefore subsequently performed two point linkage analyses using recessive, intermediate, and dominant inheritance models, all with reduced penetrance. The strongest evidence for linkage (lod = 1.42, θ = 0.1) was found to D2S378 under an intermediate model (penetrances of 0, 0.4, 0.6 for aa, Aa, AA genotypes, frequency of 25% for disease allele “A”), supporting the notion that the assumptions of the model of Fagerheim et al were less accurate for our sample. Multipoint variance component linkage analyses of the phonological awareness, phonological coding, and spelling measures produced the most significant results under a model that included QTL additive and dominance variance, polygenic additive variance, and environmental variance. The peak lod scores were 3.82 between D2S2352 and D2S378 for spelling, 1.13 at D2S378 for phonological coding, and 1.01 at D2S378 for phonological awareness. These lod scores were generated under two degrees of freedom, owing to inclusion of QTL additive and dominance variance. To allow for comparison with a traditional linkage threshold of lod = 3.0, the lod scores

Abbreviations: PCD, phonological coding dyslexia; NPL, non-parametric linkage analysis
under one degree of freedom were estimated to be 3.12 for spelling, 0.69 for phonological coding, and 0.60 for phonological awareness. Investigation of haplotypes in affected subjects failed to identify the D2S378/D2S2279/D2S2183 haplotype that cosegregated with dyslexia in the Norwegian family; however, the D2S378 allele in the Norwegian haplotype was rare in our sample (observed in only two of 877 subjects).

CONCLUSION
In conclusion, linkage analyses of dyslexia and quantitative reading measures in a large Canadian family sample have provided the first independent evidence for the DYX3 dyslexia locus on chromosome 2p15-p16, originally reported in a large Norwegian family.

ACKNOWLEDGEMENTS
We thank Dr Toril Fagerheim for Norwegian DNA samples and haplotype information, Rose Tobias, Elzbieta Swiergala, and Malgorzata Zapala for technical assistance, and the Multimedia Advanced Computational Infrastructure (MACI) cluster for computing service. This work was supported by the Alberta Mental Health Research Fund, the Alberta Children’s Hospital Foundation, the Network of Centres of Excellence Programme, grant MT-15661 from the Canadian Institutes of Health Research (formerly MRC Canada), and scholarships to TLP from the Natural Sciences and Engineering Research Council and the Alberta Heritage Foundation for Medical Research. LLF was an Alberta Heritage Medical Scientist while at the University of Calgary.

Authors’ affiliations
T L Petryshen, M L Hughes, L L Field, Department of Medical Genetics, University of Calgary, Calgary, Canada
B J Kaplan, Department of Paediatrics, University of Calgary, and Alberta Children’s Hospital, Calgary, Canada
J Tzenova, L L Field, Department of Medical Genetics, University of British Columbia and British Columbia Research Institute for Women’s and Children’s Health, Vancouver, Canada

Correspondence to: Dr LL Field, Department of Medical Genetics, British Columbia Research Institute for Women’s and Children’s Health, 950 West 28th Avenue, Vancouver, British Columbia, Canada V5Z 4H4; llfield@interchange.ubc.ca

REFERENCES

Unique de novo mutation of BRCA2 in a woman with early onset breast cancer
M Robson, L Scheuer, K Nafa, N Ellis, K Offit

Although it is widely stated that 5-10% of all breast cancers arise as the result of an inherited predisposition, the prevalence of mutations in BRCA1 or BRCA2 in unselected ascertainment of women with breast cancer is somewhat lower. In two population based series from the United States, presumably deleterious BRCA1 mutations were identified in only 14 female breast cancer patients out of a combined total of 884 women (1.6%).1,2 In two European series, BRCA1 or BRCA2 mutations were identified in 19/1035 (1.6%) Finnish breast cancer patients1 and 24/1220 (2.0%) breast cancer patients from the UK.3 Because of the low prevalence of detectable mutations, screening of unselected breast cancer patients has not been recommended. Mutation analysis is more often suggested for specific groups of breast cancer patients in whom mutations are more likely to be detected. The decision whether or not to offer genetic testing usually revolves around the presence or absence of a significant family history of breast or ovarian cancer, although age at diagnosis, bilaterality, and ethnicity may be important considerations. A negative family history, however, clearly does not exclude the presence of a germline mutation in BRCA1 or BRCA2. In a population based series from the United Kingdom, none of the 13 mutation carriers diagnosed with breast cancer before the age of 36 was reported to have had a family history of breast or ovarian cancer in first degree relatives.4 In contrast, in a series from the United States, most mutation carriers in a group of women with early onset breast cancer had a history of breast cancer in either first or second degree relatives.4 However, even in this series, one of the mutation carriers had no family history of breast cancer. The lack of a family history among mutation carriers may reflect
small family size, non-penetrance, premature death of at risk women, or inadequacy of the history information itself. A mutation carrier without a family history may represent new mutations. The proportion of BRCA mutations that arise de novo is unknown. The two cases that have been reported to date appear to be recurrent mutations occurring at sites that may be predisposed to alteration. A woman with early onset breast cancer with no family history of breast or ovarian cancer was found to carry both the BRCA1 3888delGA and the BRCA2 mutation 6174delT. While the father of the proband was shown to carry the BRCA2 6174delT mutation, which is known to be a founder mutation in people of Ashkenazi descent, neither parent carried the BRCA1 3888delGA mutation, indicating that this alteration most likely arose de novo. Interestingly, an Ashkenazi woman with both early onset breast cancer and ovarian cancer had previously been reported to carry both the BRCA1 3888delGA mutation and the BRCA2 6174delT mutation, suggesting that the BRCA1 3888delGA mutation may, in fact, be a recurrent alteration developing at a mutational hot spot. Further evidence for such areas of predisposition to mutation comes from the recent report of a woman with early onset breast cancer who carried the BRCA2 mutation 3034del4. Although this particular mutation has been described many times in families of various ethnic origins, neither of the proband’s parents carried the alteration, again suggesting a de novo origin at a genomic site prone to small deletions.

Both of the de novo BRCA1 or BRCA2 mutations that have been reported to date have been identified in other families. We now report a unique, previously undescribed de novo mutation, identified in a woman with early onset breast cancer.

CASE REPORT

The proband was a woman of Irish, Scots, and Welsh ancestry who was diagnosed at the age of 35 with bilateral infiltrating ductal carcinoma after investigation of abnormalities noted at the time of baseline mammography. She was treated with bilateral modified radical mastectomies and CMF chemotherapy. She had no family history of breast or ovarian cancer. Her mother was alive and without cancer at 71 years of age. She had five sisters, aged 32 to 47, none of whom had been diagnosed with either breast or ovarian cancer. Her father was diagnosed with colon cancer at the age of 57 and died of metastatic disease at 62. At 41 years of age, the proband enrolled in an Institutional Review Board approved study of genetic testing for hereditary breast cancer risk. After giving informed consent, she provided a sample of peripheral blood, from which DNA was extracted using standard techniques. Testing was performed at Myriad Genetic Laboratories (Salt Lake City, UT). Aliquots of DNA were subjected to polymerase chain reaction amplification and full sequence determination in both forward and reverse directions of the 23 exons of BRCA1, along with approximately 800 bp of intronic sequence surrounding the intron-exon boundaries. In addition, full sequence determination was performed of the 26 exons of BRCA2 along with approximately 900 bp of intronic sequence surrounding the intron-exon boundaries of this gene. Sequence analysis showed a single nucleotide insertion at nucleotide 7260 of BRCA2. The 7260insA insertion in exon 14 results in premature termination at codon 2359. Other than the proband, there are no reports of this alteration in the Breast Cancer Information Core database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=clinvar). The presence of the mutation was confirmed on a separate blood sample. Testing was then carried out on DNA samples obtained from the proband’s mother and five sisters, none of whom was found to carry the mutation. Repeat testing of each of these family members was performed and confirmed the absence of the mutation in all.

To investigate the possibility of a de novo mutation, the paraffin embedded samples of the proband’s father’s colon cancer specimen were retrieved. DNA was extracted using standard techniques and analysed for the presence of the BRCA2 7260insA mutation. The mutation was not identified in the father’s sample on initial or repeat analysis. To establish paternity, both parents and all sibs who had donated samples for DNA analysis were genotyped at three polymorphic loci (MYC-L1, D2S123, D17S250). The results of this genotyping are consistent with the reported paternity.

DISCUSSION

To our knowledge, this is the first report of a unique de novo mutation in either BRCA1 or BRCA2. Although this specific mutation has not previously been described, several other presumably deleterious alterations have been reported in its vicinity in exon 14. Examples include BRCA2 7253delAA (reported four times), 7297delCT (reported five times), and 7252C→T (Q2342X, reported once). This portion of the BRCA2 gene may therefore represent an area of susceptibility to new mutational events. The prevalence of de novo mutations in BRCA1 and BRCA2 is unknown. Although one would hypothesise that previously unreported mutations would be more likely to be the result of new mutational events, the recurrent nature of the two previously reported de novo alterations indicates that this criterion is not a reliable discriminator.

The identification of this mutation illustrates that analysis of BRCA1 and BRCA2 may be productive in the absence of a family history of breast or ovarian cancer. Empirical models estimating the likelihood of identifying germline mutations, such as BRCAPRO, are based upon the pattern of diagnoses within a family as a whole and have not been validated in women without a family history. Studies from the United Kingdom and United States have indicated that 5.9-9.4% of women diagnosed with breast cancer at the age of 35 or younger will have a detectable germline BRCA mutation. While many of these women will have a family history of breast or ovarian cancer, it is clear from the reported series that some will either have no such history or will only report breast cancer diagnoses in relatives of second or greater degree. Women with BRCA mutations are at increased risk of metachronous contralateral cancer, and it is therefore logical to assume that the presence of bilateral disease would increase the likelihood of detecting a germline mutation. However, the degree to which the presence of bilateral disease influences this probability has not been defined. Other factors, such as lack of hormone receptor expression, medullary histology, or high histological grade may also indicate an increased probability of germline mutation, although none of these are absolute discriminants.

The information derived from genetic testing of women with very early onset breast cancer may substantially influence clinical management. For example, after the mutation was identified, the proband underwent bilateral salpingo-oophorectomy in an attempt to reduce her ovarian cancer risk. Other women may elect to forego breast conservation therapy and undergo bilateral risk reducing mastectomy to address the substantial risk of metachronous contralateral disease. Because of the significant clinical implications both for the affected subject and for her family, as well as the less than complete sensitivity of a family history of breast cancer, consideration should be given to providing genetic counselling and discussing BRCA genotyping with all women with early onset breast cancer. The existence of de novo BRCA mutations should also be taken into account when generating penetrance estimates from genetic epidemiology studies. For instance, the kin-cohort model assumes that affected parents are obligate heterozygotes. The violation of this assumption by occurrence of de novo mutations may lead to underestimation of penetrance by this and similar models.
A variant of osteogenesis imperfecta type IV with resolving kyphomelia is caused by a novel COL1A2 mutation

M T Johnson, S Morrison, S Heeger, S Mooney, P H Byers, N H Robin

Conflict of interest

Correspondence to: Dr Robson, Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA; robsson@mskcc.org

REFERENCES


shown that she has a variant of OI. The histories of her two affected children are also presented to provide insight into the prenatal and neonatal manifestations of this disorder.

**CASE REPORTS**

The proband is a 35 year old woman who presented at 23 weeks' gestation following a routine fetal ultrasound that showed generalised rhizomelic and mesomelic shortening of the limbs with severe angulation malformations of the femora (fig 1). In reviewing her past medical history, the proband reported that she was born with severely bowed legs. Review of films from infancy showed that she had rhizomesomelic shortening of the lower extremities with severely bowed femora and fibulae, and Wormian bones in the calvarium (fig 2A). At the age of 3 months, she was diagnosed with osteogenesis imperfecta after a reportedly normal evaluation for hypophosphatasia. From approximately 3 months to 1 year of age, her legs were maintained in full length plaster casts, which slightly improved the bowing (fig 2B). After starting to walk, her lower limbs showed dramatic improvement over the subsequent year (fig 2C). The proband also has a history of significant dental decay, particularly involving the primary teeth. A recent dental evaluation has shown that her dental abnormalities are consistent with dentinogenesis imperfecta. She bruises easily and has broken three bones in her life time, each after significant trauma. Over the past few years, she has developed worsening lumbar spondylolisthesis. Her intellectual development was normal and she has neither hearing loss nor joint laxity. There is no previous family history of short stature, blue sclerae, poor dentition, osseous fragility, easy bruising, hearing loss, or joint laxity.

At presentation, she had a height of 147 cm (below the 5th centile) with a weight and head circumference measuring within the 50th-75th centiles. Her upper to lower segment ratio and arm span to height ratio were on the 95th centile. She had pale blue sclerae and teeth with translucent enamel and multiple caries. Her limbs were normally proportioned without joint laxity or limitation. Her skin had normal elasticity and there were no abnormal scars. A radiological survey of her skeleton showed femora with very mild varus deformities (fig 2D). Other abnormalities noted in the skeletal survey included a malunion fracture of the left clavicle, grade 3 spondylolisthesis involving the L5-S1 vertebral bodies, and Wormian bones in the calvarium. She had no radiographic signs of osteopenia or anomalies of the scapulae or vertebrae.

The proband’s pregnancy was followed with serial ultrasonographic evaluations at 28 and 32 weeks’ gestation. The fetal femora showed worsening of bowing during gestation with lengths following established growth curves, but remaining below the 3rd centile. In contrast, bilateral tibial and unilateral radial bowing noted in the initial sonogram improved during gestation. The final sonogram also noted slightly decreased echogenicity of the calvarium.

At 39 weeks’ gestation, a male infant was delivered by caesarean section because of a history of a previous low transverse caesarean section. The infant weighed 2685 g (between the 5th and 10th centiles), measured 43.5 cm in length (below the 5th centile, median height of 33 weeks’ gestation), had a crown-rump length of 33.5 cm (50th centile), and a head circumference of 34.5 cm (between the 25th and 50th centiles). His sclerae had a faint bluish hue and his face had no appreciable dysmorphic features. The chest was normally shaped with a circumference measuring between the 25th and 50th centiles. The only anomalies noted on physical examination were severe varus deformities of both thighs without dimpling of the overlying skin. Radiographic skeletal survey showed femoral bowing with slight metaphyseal flaring. Wormian bones, and the presence of only 11 ribs bilaterally (fig 3). The
infant had an uncomplicated course during the neonatal period and was healthy during early infancy. However, he died unexpectedly at 6 weeks of age with the cause of death being attributed to sudden infant death syndrome (SIDS). Necropsy showed abnormal rib morphology with anterior flaring and evidence of a healing left femoral fracture. Histological analysis of samples from the left femur, skull, and ribs showed osteopenia and focal areas of marrow fibrosis.

In a subsequent pregnancy, prenatal ultrasonography at 18 weeks’ gestation identified a fractured right femur, bowed right tibia, fractured right humerus, and shortened and bowed left femur. A follow up sonogram at 34 weeks’ gestation showed worsening of the bowing of the femora and tibiae. Following a term pregnancy, a female was born by caesarean section with a weight and head circumference falling within the 25th-50th centiles whereas the length of 40.5 cm fell below the 5th centile. Physical examination at birth was notable for grey sclerae, rhizomelic shortening of all extremities, and dimpling over the lateral aspects of the midshafts of the femora and humeri. A radiographic survey of the skeleton showed diffuse osteopenia, several enlarged costochondral junctions consistent with healing fractures, and bilateral shortening and bowing of the femora and tibiae. A radius to humerus ratio of 0.91 confirmed rhizomelic shortening of the upper extremities according to standard curves.

**Molecular studies**

A skin biopsy was obtained from the forearm of the proband with appropriate consent, and fibroblasts were grown by routine methods. The collagens and procollagens synthesised by these cells were analysed as previously described. The cells were found to produce both a normal and an abnormal species of type I procollagen (fig 4A, B). In the latter, the chains were overmodified along the amino-terminal 40% of the triple helical domain, consistent with a mutation in either the COL1A1 or COL1A2 gene. Exons 6-52 of the COL1A1 and COL1A2 genes were amplified by PCR and screened for mutations by conformation sensitive gel electrophoresis. Several heteroduplexes were identified and the sequence of the exon and flanking splice junctions were determined for each. The only pathogenic abnormality identified was a G to C transition (1406G→C) with the A of the initiator methionine as the nucleotide at position 1 of the mRNA, CAGGCCTC→CAGGCCCTC in one allele (fig 4C). This sequence alteration is predicted to result in substitution of the glycine at position 379 of the triple helical domain of the protε(1) chain by alanine (G379A, in which the first glycine of the triple helix is referred to as the index position or G469A when the initiator methionine is the reference point). Karyotypic analysis of the male first child showed a normal 46,XY genotype.

**DISCUSSION**

The mild skeletal abnormalities, short stature, and dentinogenesis imperfecta combined with the molecular studies confirm that the proband and her children have osteogenesis imperfecta type IVB. The persistent pale blue sclera is uncommon in OI type IV, but can be seen in up to 10% of affected subjects. The striking improvement of the congenital deformities, to our knowledge, has not been reported in OI type IV. Improvement of femoral bowing in OI has only been described for type I, and there is little documentation of the natural history of the improvement in these cases. An interesting aspect of the improvement in femoral bowing noted in this report is that it coincided with the start of walking, which may suggest that weight bearing plays a role in the remodelling process.

Before the type I collagen studies, the diagnoses of osteogenesis imperfecta and kyphomelic dysplasia were both considered. Initially, the diagnosis of KD seemed more likely owing to the natural history of the proband’s femoral bowing and phenotypic features in her infants, such as cutaneous dimpling over bowed femora, metaphyseal irregularities, and 11 pairs of ribs with flaring at the costochondral junctions. However, the identification of a type I collagen mutation established the diagnosis of osteogenesis imperfecta type IV for these affected family members. This report provides further evidence that at least some of the cases of apparent kyphomelic dysplasia are actually mild or atypical forms of other skeletal dysplasias. To our knowledge, no other cases of presumed KD have been examined molecularly. As other cases confirming the diagnosis of KD are analysed for mutations in either the type I collagen genes or Perlecán, the gene recently shown to be mutated in cases of Schwartz-Jampel syndrome, it should be possible to determine whether KD exists as a specific diagnostic entity.

Type I collagen is a triple helix composed of two chains encoded by the COL1A1 gene and one chain encoded by the COL1A2 gene. In the more than 200 mutations identified in these two genes, there are no predominant mutations and most mutations are restricted to single families. The majority of mutations in both genes result in single amino acid substitutions for glycine residues within the triple helical domain of the chains. In this region, glycine occurs in every third position of the collagen triple helix. Of the 55 missense substitutions described
in the COL1A2 gene that replace glycine residues, only two mutations have resulted in substitutions with alanine (at positions 199 which results in OI type IV\(^2\) and 1006 which results in OI type III\(^2\)). Alanine codons result from substitutions for the second position G by C in all glycine codons (GGN). These substitutions are rare in both type I collagen genes and in the type III collagen gene (COL3A1), mutations which result in Ehlers-Danlos syndrome type IV phenotype.\(^24\) There appear to be two possible explanations for the low frequency of these substitutions: either the phenotypes do not correspond to those produced by other substitutions for glycine because of the low bulk of the side chain methyl group, or G→C transversions in these codons are uncommon. There are insufficient data to distinguish between these two possibilities, although substitutions for glycines at positions 910\(^2\) and 928\(^2\) in the COL1A1 gene both result in the classical lethal OI type II phenotype, and neither of these cases, to our knowledge, has features of resolving kyphomelia. Thus, mutation frequency may be the more likely explanation.

The clinical courses of the infants presented in this report raise several important points. First, the significant prenatal bowing at 18 weeks' gestation would have raised a greater degree of concern for a more severe form of OI or other skeletal dysplasia had it not been for the natural history of the mother. The lack of multiple fractures in the femora and the absence of significant demineralisation of the calvaria in the early stages of both pregnancies argued against a lethal form of a skeletal dysplasia,\(^27\) but the significant deformities with progression throughout pregnancy were felt to be consistent with a number of more severe syndromes, such as OI type III, Stüve-Wiedemann syndrome, or Schwartz-Jampel type 2 syndrome.\(^28\) This case suggests that a potentially mild clinical course can follow when angulated femora are detected in early pregnancy or at birth. Second, the early death of the male infant in this report prompted a review of infant mortality in cases of apparent KD and OI. A recent review of the majority of reported cases with presumed KD noted that four out of 12 babies died between 2 and 13 months of age with the cause of...
death being unclear in several cases. Temple et al. described a single case of an infant with apparent KD who had documented episodes if apnoea, including one life-threatening episode, between the ages of 4-6 months. In contrast, there were no cases of infant mortality in a review of causes of death in 79 patients with confirmed OI (type II excluded). The risk of infant mortality in variants of OI with resolving kyphomelia will only become established as more cases are identified.

This case report expands the phenotypic and molecular spectrum of OI type IV. This phenotype with its remarkable natural history is important to appreciate for clinicians who encounter fetuses or neonates with bowing of the femora. The incorporation of this phenotype into the diagnostic category of OI supports the view that congenital bowing of the femora, even if there is striking resolution during infancy, should be considered as a symptom rather than a specific disease. The expanding range of prognoses associated with congenital bowing of long bones provides an impetus for pursuing genotype-phenotype correlations in these cases.

ACKNOWLEDGEMENTS

This work was supported in part by a grant from the National Institutes of Health, AR41223.

Authors’ affiliations

M T Johnson, S Heeger, N H Robin, Center for Human Genetics, University Hospitals of Cleveland, Cleveland, OH, USA

M T Johnson, N H Robin, Department of Pediatrics, University Hospitals of Cleveland, Cleveland, OH, USA

S Morrison, Department of Radiology, Cleveland Clinic Foundation, Cleveland, OH, USA

S Mooney, P H Byers, Departments of Pathology and Medicine, University of Washington, Seattle, WA, USA

Correspondence to: Dr N H Robin, Center for Human Genetics, Lakeside 1500, Cleveland, OH 44106-6506, USA; nhr2@po.cwru.edu

REFERENCES


Functional characterisation of MeCP2 mutations found in male patients with X linked mental retardation

S Kudo, Y Nomura, M Segawa, N Fujita, M Nakao, S Hammer, C Schanen, I Terai, M Tamura

Rett syndrome is a neurodevelopmental disorder that primarily affects females and is characterised by a period of normal growth and development, followed by severe neurological dysfunction including dementia, autistic features, loss of purposeful use of the hands, jerky truncal ataxia, and seizures. Systematic genetic analyses have shown that mutations in the methyl-CpG binding protein gene MeCP2 are associated with Rett syndrome. Recently, MeCP2 mutations

www.jmedgenet.com
(A140V and E137G) were also found in male patients with non-specific X linked mental retardation that is clinically distinct from Rett syndrome. To elucidate the functional significance of these mutations, we used transient expression assays to compare the effects of these mutations on MeCP2 function with those of Rett syndrome mutations. Wild type and mutant MeCP2/GFP fusion proteins expressed in mouse L929 cells were analysed to determine the effect of mutations on accumulation of MeCP2 in heterochromatin, where approximately half of the methyl-CpG dinucleotides occurring in the genome are located. In contrast to an R106W Rett syndrome mutant protein, which has no affinity to heterochromatin, both A140V and E137G mutants showed a clear focal heterochromatin staining pattern indistinguishable from the wild type protein. The effects of mutations on transcriptional repressive activities were also evaluated in Drosophila SL2 cells, which possess only marginal background activities of methyl-CpG binding proteins. Although R106W expression substantially reduced transcriptional repressive activity, the A140V and the E137G mutants retained the transcriptional repressive activity. In particular, the A140V mutant retained such repressive activity at a level comparable to the wild type protein. These results indicate that potential alterations in MeCP2 function resulting from the A140V and the E137G mutations are different from those associated with mutations observed in Rett syndrome and may explain why the manifestation of MeCP2 related mental disorder in males is clinically different from Rett syndrome.

MATERIALS AND METHODS

MeCP2 cDNA bearing missense mutations were generated by site directed mutagenesis using mismatched primers as described previously. A full length MeCP2 cDNA was used as a template for PCR. Insert of the A140V or E137G mutant DNA was cloned into the BspEI and HfrI sites of pEGFP-C1 (Clontech), an enhanced fluorescence vector, and the EcoRI and BamHI sites of the Drosophila expression vector pAc5.1/V5-His (Invitrogen). Mouse L929 cells were transfected with GFP expression constructs using Superfect (Qiagen). Two days later, cells on chamber slides were fixed with 3.7% formaldehyde for 10 minutes, permeabilised with 0.5% Triton X-100 for 20 minutes, and counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma). The specimens were observed under an Olympus fluorescence microscope using the appropriate optical filter. The transient expression analysis using Drosophila SL2 cells was performed as follows. The SNRPN-luciferase reporter construct was treated with SspI (CpG) methylase (New England Biolabs) in the presence of 5 mmol S-adenosylmethionine as described previously. A total of 1.4 × 10⁷ SL2 cells were grown in 0.7 ml of Schneider’s Drosophila medium in a 24 well plate. A total of 0.4 µg of the luciferase reporter construct was cotransfected with 0.2 µg of an Sp1 expression plasmid, pPacSp1, 0.01 µg of pAc5.1-pRL, and various amounts of expression plasmid (1-100 ng) bearing genes encoding MeCP2 mutants into Drosophila SL2 cells by the calcium phosphate method. The total amount of transfected DNA was adjusted by adding pAc5.1.V5-His vector. After 48 hours, the cells were lysed with 100 µl of lysis buffer and 10 µl of lysate was assayed for firefly and Renilla luciferase activities using the Dual-Luciferase reporter assay system (Promega). All transient transfection assays were carried out at least three times independently.

RESULTS

Recently, novel mutations in the methyl-CpG binding domain (MBD) of MeCP2 were reported in males affected by a mental retardation disorder that is clinically distinct from Rett syndrome. The E137G mutation was found in a family in which affected males showed profound to mild mental retardation, often associated with speech handicap. The A140V mutation was found in a family, four adults, severely mentally retarded brothers, with mild mental retardation in their mother and sister. The A140V mutation was also found in sporadic cases of moderate to severe mental retardation in males. It has been assumed that males who are hemizygous for mutations in MeCP2 die prenatally or early in infancy with a severe congenital encephalopathy. Therefore, survival of male patients exhibiting mental retardation into adulthood suggests that the activities of these novel mutant proteins are functionally distinct from that of MeCP2 mutant proteins seen in Rett syndrome. In order to investigate the functional consequences of the A140V and E137G mutations, we used a heterochromatin staining analysis, which was initially used to characterise Rett syndrome mutations. This analysis takes advantage of the unique feature of mouse L929 cells, which have approximately half of the methyl-CpG dinucleotides clustered in the pericentromeric heterochromatin. Thus, exogenously expressed MeCP2 accumulates in this region and can be detected by fluorescence microscopy as distinct foci. Such accumulation of MeCP2 in heterochromatin is not observed in human or rat cells. Loss of MBD function leads to a decrease in the intensity of focal staining and an increase in staining throughout the nucleus. Therefore, the effect of MBD missense mutations on methyl-CpG binding activities can be indirectly assessed. Using this system we compared the activities of the A140V and the E137G mutant proteins with that of wild type protein and with two common Rett syndrome mutations, R106W and T158M. A previous study showed that fusing MeCP2 mutant proteins with GFP did not affect their nuclear localisation, so mutants were expressed as GFP fusion proteins. Mouse L929 cells were transfected with GFP fusions of wild type and mutant proteins, and intranuclear localisations of proteins were examined. The result of this analysis is summarised in fig 1. MeCP2-GFP was predominantly...
localised to heterochromatin regions of mouse L929 cells, which were identified by co-localisation of strong DAPI staining. As reported previously, R106W-GFP showed no clear focal staining in the nucleus and fusion proteins were distributed throughout the nucleus. Impairment of heterochromatin staining was also observed with the T158M-GFP construct, although the effect was milder than that of R106W. Some focal staining in a background of nuclear staining is still apparent. By contrast, both A140V-GFP and E137G-GFP fusion proteins showed the distinct foci in the nucleus, which matched with DAPI staining, indicating that the mutant proteins were predominantly localised to heterochromatin. These staining patterns are indistinguishable from that of the wild type protein, indicating that the A140V and the E137G mutants retain substantial affinities for heterochromatin and their abilities to bind methyl-CpG are not obviously affected.

To delineate the effects of the A140V and the E137G mutations on the transcriptional repressive activity of MeCP2, we used transient expression in a Drosophila cell line. It is known that Drosophila cells have very low levels of DNA methylation and exhibit extremely low levels of the DNA methyltransferase activity and methyl-CpG binding activities. These observations suggest that regulation by DNA methylation is negligible in Drosophila cells. On the other hand, the general transcriptional machinery is thought to be highly conserved between Drosophila and mammals. Our previous studies indicated that wild type MeCP2 expressed in Drosophila SL2 cells repressed Sp1 activated transcription on a methylated promoter, indicating that SL2 cells are suitable to evaluate MeCP2 repressive activity. Here, we used a construct containing the luciferase reporter driven by the promoter of the human imprinted SNRPN gene. This SNRPN promoter provides high transcriptional activity and is highly sensitive to MeCP2 transcriptional repression. Drosophila expression constructs encoding wild type or a mutant MeCP2 were cotransfected into SL2 cells with the reporter plasmid and an Sp1 expression vector, as well as the pAc5.1-pRL control plasmid for normalisation. The results of this analysis are shown in fig 2. As shown previously, wild type MeCP2 sharply reduced Sp1 activated transcription in a dose dependent manner. Transcriptional activity was reduced approximately 30-fold at the highest dose (100 ng). On the other hand, cotransfection with R106W had little effect on transcription from the methylated template; transcription was repressed approximately 40% at the highest dose, indicating that R106W mutant protein significantly lacks repressive activity.

Intermediate levels of transcriptional repression were seen with the T158M mutant. Transcriptional repressive activity of T158M was slightly stronger than that of R106W, showing five-fold repression of transcription at the highest dose. The E137G mutant showed the transcriptional repressive activity similar to that of the T158M mutant when the promoter was methylated. On the other hand, the A140V mutant strongly repressed transcriptional activity, showing a steep dose response curve compared to that of the wild type protein. Thus, the A140V mutant retains substantial repressive activity on a methylated promoter. Interestingly, the ability of the A140V mutation to repress transcription from an unmethylated SNRPN promoter was also significantly enhanced, reducing luciferase activities by approximately five-fold at the highest dose (100 ng), while the wild type protein reduced transcription by only about 40% at the same dose. In this study, we also examined expression levels of expressed wild type and mutant MeCP2 proteins by indirect immunofluorescence and western blot analysis, and found that the proteins expressed from these plasmids were produced in the nucleus at similar levels following transfection (data not shown). Table 1 summarises these two transient expression analyses.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Nuclear staining in L929 cells</th>
<th>Transcriptional repressive activity in SL2 cells</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt</td>
<td>Distinct foci</td>
<td>Strong</td>
<td>Normal</td>
</tr>
<tr>
<td>A140V</td>
<td>Distinct foci</td>
<td>Strong</td>
<td>Non-specific X linked mental retardation</td>
</tr>
<tr>
<td>E137G</td>
<td>Distinct foci</td>
<td>Moderate</td>
<td>Non-specific X linked mental retardation</td>
</tr>
<tr>
<td>T158M</td>
<td>Distinct foci + diffuse staining</td>
<td>Moderate</td>
<td>Rett syndrome</td>
</tr>
<tr>
<td>R106W</td>
<td>Diffuse staining</td>
<td>Weak</td>
<td>Encephalopathy in boy</td>
</tr>
</tbody>
</table>

Table 1: Summary of the effects of mutations
on these results, the A140V and the E137G mutants retain more residual function in terms of heterochromatin binding and transcriptional repression than two common Rett syndrome mutants. This observation may explain why male patients carrying these novel mutations survive into adulthood with mental retardation, a phenotypic manifestation different from that seen in Rett syndrome.

DISCUSSION
MeCP2 mutations were initially found in patients with Rett syndrome, which occurs almost exclusively in females. Mosaic expression of normal versus abnormal alleles resulting from X chromosome inactivation probably contributes to the survival of female patients and also the severity of Rett syndrome, while males who are hemizygous for mutations in MeCP2 most often present with a severe congenital encephalopathy associated with decreased survival. Similarly, MeCP2 null mice and mice undergoing conditional knockout of MeCP2 before birth can survive and develop symptoms characteristic of Rett syndrome after weaning.

The recent findings of MeCP2 mutations in adult males with non-specific X linked mental retardation suggest that the altered activities of these mutant MeCP2 proteins are responsible for these phenotypes. To address this question, the functions of these novel mutant proteins were examined by two assays and the results were compared to similar assays with known Rett syndrome mutant proteins. A previous study showed that most missense mutations in MBD of MeCP2 substantially reduced the affinity of MeCP2 for heterochromatin. These mutations abolished the repressive activity of MeCP2 on Sp1 activated transcription from a methylated promoter. Mouse heterochromatin is known to contain satellite DNA, which possesses highly methylated CpG dinucleotides. It has been shown that the accumulation of MeCP2 in mouse heterochromatin requires both methylated CpG and the MBD. Therefore, the accumulation of MeCP2 in heterochromatin depends primarily on the ability of MBD to bind to methylated DNA. Heterochromatin staining analysis of L929 cells showed that A140V-GFP and E137G-GFP fusion proteins exhibited clear focal staining in the nucleus, a pattern similar to that seen in the wild type protein, indicating that the binding affinities to methylated CpGs are not decreased by these mutations. Transient transfection of Drosophila SL2 cells also enabled us to evaluate the consequences of these novel mutations on MBD function. A previous study showed that C-terminal truncated MeCP2, which contains the MBD but not the transcriptional repression domain (TRD), exhibited substantial transcriptional repressive activity in Drosophila cells. Therefore, it is likely that transcription is repressed primarily by steric hindrance induced by MeCP2 binding to methylated CpGs, making the promoter inaccessible to activators. However, in this system, active transcriptional repression may also be partially functional owing to interaction between the TRD and histone deacetylase complex. In fact, the histone deacetylase inhibitor tricostatin A (TSA) relieved the transcriptional potential and the efficiency of recovery varied depending on the promoter context (data not shown). Since binding of the MBD to methylated DNA is a prerequisite for recruitment of histone deacetylase, the effect of the MBD mutation on transcriptional repression can be assessed in our Drosophila system. Transient expression of the A140V mutant in Drosophila SL2 cells showed that this mutant retained considerable ability to repress Sp1 activated transcription from a methylated reporter. Intriguingly, the A140V mutant showed stronger repression of transcription from an unmethylated reporter than did the wild type protein. It is noteworthy that the R106W mutant, which had low affinity to heterochromatin, completely failed to repress Sp1 activated transcription from an unmethylated template (fig 2). It has been shown that the region flanking the carboxy side of MBD is involved in binding to unmethylated DNA. Our transcription analysis in SL2 cells suggest that in addition to that region, the MBD itself contains a region involved in non-specific binding to unmethylated DNA. Although further studies are required to show the significance of MeCP2 affinity to unmethylated DNA, it is possible that higher affinity binding owing to the A140V mutation affects the proper gene expression although methylated genes are normally controlled. NMR spectroscopy analyses have shown that an alanine at amino acid residue 140 is present in the middle of the α helix of MeCP2. Therefore, a mutation in this locus may not significantly change the folding of the MBD structure and would barely perturb its binding to methyl-CpG base pairs; however, such a mutation may increase the affinity for unmethylated regions. Although we cannot rule out the possibility that the A140V mutation is not a disease causing mutation but just a polymorphism, transcriptional repressive effect of this mutation on the unmethylated gene is apparently different from that of wild type. This change of the MeCP2 function may result in an aberrant pattern of gene expressions in relevant tissues. On the other hand, the E137G mutation exhibited further impairment of the transcriptional repressive function in our Drosophila assay, even though this mutant possessed the mouse heterochromatin affinity comparable to that of wild type. The effect of the E137G mutation on the transcriptional repressive activity to the methylated promoter was almost equal to that of the T158M mutation (fig 2). Recently, the T158M mutation was observed in two brothers of a patient with classical Rett syndrome. Both brothers died within a year of birth, and one suffered from severe encephalopathy. Our functional analyses show that T158M had intermediate affinity to heterochromatin and moderate effects on transcriptional repressive activity. These results are consistent with reports that the T158M mutant exhibited only slightly lower binding affinity for methylated DNA compared with that of the wild type protein. Thus, mild impairment of MeCP2 function owing to mutations may result in MeCP2 associated mental retardation or severe encephalopathy in males. Taken together, these observations suggest that the MeCP2 mutations give rise to a variable range of neurodevelopmental disorders dependent on the functionality of the protein.

ACKNOWLEDGMENTS
We thank Drs Kei Fujinaga and Takeo Kubota for helpful discussions and Dr Ellen E Lamar for critical reading of the manuscript. This work was supported by the Akiyama Foundation.

Authors' affiliations
S Kudo, I Terai, M Tamura, Hokkaido Institute of Public Health, Sapporo 060-0819, Japan
Y Nomura, M Segawa, Segawa Neurological Clinic for Children, Tokyo 101-0062, Japan
N Fujita, M Nakao, Department of Tumor Genetics and Biology, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan

www.jmedgenet.com
Acrofacial dysostosis in a patient with the TSC2-PKD1 contiguous gene syndrome

J G Dauwverse, K Bouman, A J van Essen, A H van der Hout, G Kolsters, M H Breuning, D J M Peters

The acrofacial dysostoses (AFDs) are a heterogeneous group of disorders characterised by defects in craniofacial and limb development. The hallmarks include downward slanting palpebral fissures, malar hypoplasia, and receding chin (retrognathia) combined with variable limb malformations. The predominantly preaxial form is called Nager AFD and the predominantly postaxial form is called Genée–Parker syndrome. The predominantly preaxial form is called Nager AFD, which is characterised by downward slanting palpebral fissures, malar hypoplasia, and receding chin. The predominantly postaxial form is called Genée–Parker syndrome. The predominantly preaxial form is called Nager AFD, which is characterised by downward slanting palpebral fissures, malar hypoplasia, and receding chin. The predominantly postaxial form is called Genée–Parker syndrome.

The second gene for TSC2, TSC2, maps to chromosome 16p13.3 tail to tail with the major gene for autosomal dominant polycystic kidney disease (ADPKD), the PKD1 gene.
These genes are separated by 63 bp. The main symptom of ADPKD is the occurrence of a large number of fluid filled cysts in the kidneys. Cysts can in general be detected by ultrasonography or CT scanning around the second or third decade of life and end stage renal failure occurs at a mean age of 53 years in PKD1 patients. ADPKD is a systemic disorder with possible extrarenal manifestations such as cysts in other organs (particularly the liver), hypertension, cardiac valve abnormalities, and cerebral aneurysms. Features of TSC and ADPKD have been observed in patients with a TSC2-PKD1 contiguous gene syndrome. In these patients, a large portion of the adjacent TSC2 and PKD1 genes has been deleted on one chromosome. In a study by Sampson et al., 17 of 22 patients with such a deletion were diagnosed with a very severe form of polycystic kidney disease, already manifesting within the first year of life.

We present a patient with an acrofacial dysostosis-like phenotype, TSC, and ADPKD. Fluorescence in situ hybridisation (FISH) analysis showed a microdeletion of approximately 280 kb including the TSC2 and PKD1 genes on chromosome 16p13.3. The deleted region is gene rich and we propose that haploinsufficiency of one of the deleted genes is responsible for acrofacial dysostosis or that the deletion has exposed a mutation in a gene on the non-deleted chromosome. An interesting candidate gene is E4F1, belonging to the GLI-Kruppel family of transcription factors.

**PATIENT AND METHODS**

**Patient**

The patient, 42 years old, had moderate mental retardation with hearing loss and mild renal impairment. Several dysmorphic features were observed (fig 1), including a long face with hypoplastic malae and retrogrowth, a low nuchal hairline, downward slanting palpebral fissures, simply formed ears, a large nose with a high nasal bridge, full lips and a high arched palate, adenoma sebaceum on the chin and in the nasolabial region, and a webbed neck. He had finger-like thumbs, clinodactyly of the second finger of the right hand, and a subungual fibroma on the third finger. There was cutaneous syndactyly of the second and third fingers of the left hand. He had a wide space between the first and second toe of his feet and subungual fibroma on the second and third toe of the right foot and on the third toe of the left foot. X rays showed a triphalangeal thumb on the right hand but not on the left hand. The second and third cervical vertebrae were fused. On his back were two shagreen patches. Further investigation, following the tuberous sclerosis protocol including MRI of the brain and echocardiography, was refused. A CT scan of the abdomen was, however, performed at the age of 44 years, showing enlarged cystic kidneys and multiple cysts in the liver, as seen in ADPKD. In the following 14 months plasma creatinine levels increased from 320 to 500 µmol/l indicating decline of renal function. The patient suffered from...
hypertension and progressive anaemic symptoms. Haemodialysis was started but this treatment was not well tolerated, and the patient died after three months. Necropsy was not performed. Family history was negative for tuberous sclerosis, polycystic kidney disease, and dysmorphic features. A diagnosis of tuberous sclerosis with an acrofacial dysostosis-like phenotype and polycystic kidneys was made.

**Cyto genetic analysis**

Chromosome analysis on cultured peripheral blood lymphocytes was performed according to standard G banding procedures. For fluorescence in situ hybridisation (FISH), metaphase preparations from EBV transformed harvested cells were prepared as described by Landegent et al. FISH analysis was performed as described previously with all cosmids and PAC clones. Fine mapping of the deletion breakpoints was done by fibre-FISH using PAC clone 64.12C and 77.3D according to the protocol described by Giles et al.

**Clones**

Chromosome 16 cosmids encompassed the TSC2 gene (LADS4, ZD5S33), the Pkd1 gene (ZD5S, REP59, 2H21), and cosmids located more proximally (cos 3, provided by Dr S Reeders, Yale, USA, 218+218.101) or more distally (UW3+5, cos2B, cos409) from the region. Chromosome 16 PACs were 109.8C, 77.3D, 91.8B, 97.10G, 91.8F, 96.4B, and 64.12C.

**Database analysis**

Blast searches of the databases of the National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov) were performed using the DNA sequences of ESTs or predicted transcripts and to obtain the sequences of PAC clones. The NIX program at www.hgmp.mrc.ac.uk, which is a tool for identifying unknown nuclearic acid sequences, was used to analyse the sequences of the PAC clones 1.8F and 96.4. Gene predictions are now also available using the map viewer on the NCBI website. (Accession numbers: PAC clone 47-2H, AC005363; PAC clone 109.8C, AC005606; PAC clone 109.9G, AC005600; PAC clone 1.8F, AC00711; PAC clone 96.4B, AC005212.)

### RESULTS

The patient is a man with an acrofacial dysostosis-like phenotype, tuberous sclerosis, and cystic kidneys; the latter were not initially noticed. Cyto genetic analysis showed a normal male karyotype. Whether a chromosomal aberration involving the TSC1 gene on chromosome 9q34 had occurred was initially investigated, as Zori et al2 described a patient with Nager anomaly and an apparently balanced translocation, 46,X,t(X;9)(p22.1;q32). DNA analysis using highly polymorphic microsatellite markers flanking the TSC1 gene on chromosome 9 did not show a deletion (data not shown). After renal impairment and polycystic kidneys had been detected, FISH analysis with cosmids mapped to chromosome 16p13.3 was performed, showing that the cosmids encompassing the TSC2 gene (LADS4, ZD5S33) and the Pkd1 gene (ZD5S, REP59, 2H21) were deleted on one copy of chromosome 16. We defined the deletion boundaries using a set of overlapping P1 clones (fig 2) and observed a deletion of (large parts of) P1 64.12C, 96.4B, 1.8F, 97.10G, 91.8B, and 77.3D. We did, however, detect signals more proximally on chromosome 16 for the P1 clones 97.10G and 91.8B as well as for the cosmids REP59 and 2H2, as these clones contain (part of) a 40 kb repeated region within the Pkd1 gene and recognise several copies of the homologous sequence located on chromosome 16p13.1.

The P1 clones 64.12C, 96.4B, and 77.3D gave weaker than expected signals, indicating that part of these clones were deleted. Using fibre-FISH with clones 64.12C and 77.3D, the deletion breakpoints were precisely mapped. Fig 2 shows a fusion of the signals of these two P1s, which on fibres of the normal chromosome 16 are 200 kb apart. As several of these clones have been sequenced by the Center for Human Genome Studies (DOE Joint Genome Institute, Los Alamos National Laboratory), we could improve the physical map of this chromosomal region. However, a few small gaps still exist in the sequence and only a draft sequence is available for clone 1.8F. We concluded that the deletion ranges from the middle of P1 clone 64.12C to the middle of P1 clone 77.3D and estimated the size to be approximately 280 kb.

### Sequence analysis

The acrofacial dysostosis-like phenotype suggests that besides the Pkd1 and Tsc2 genes, one or more additional genes are contributing to the patient's phenotype. From centromere to telomere, genes encoding the following proteins are deleted. The ABC3 transporter (L48758, L48760, L75924, L75925) is involved in transport of molecules into or out of cells and across subcellular membranes. The human S phase prevalent DNA/RNA binding protein RNPS1 (accession No L75926 and L75927) is suggested to be involved in splicing or in processing of precursor RNAs into mature mRNA. Dodecenoyl-coenzyme A delta isomerase (DCI) is a mitochondrial 3,2-trans- enoyl-coenzyme A isomerase suggested to have a role in oxidation of unsaturated fatty acids. The deoxyribonuclease I-like2 (DNASE1L2) gene is related to deoxyribonuclease I, which plays a role in the breakdown of nucleic acids in the gastrointestinal tract. An additional role for deoxyribonuclease I in apoptosis have been proposed. The exon has also been proposed to be involved in DNA repair. However, it still to be elucidated. The adenovirus E1A regulated transcription factor E4F1, the human homologue of the transcription factor pAP3 (accession No L48762, L48763), is a negative regulator of genes encoding proteins responsible for the inhibition of the cell cycle. The human homologue of the rat RAB26 ras related GTPase (L48770, L48771), which is a GTP binding protein involved in vesicular transport, is the final deletion.

The following genes are located distally from the Pkd1 and Tsc2 genes. The endonuclease III-like 1 gene (NTLH1) located in the P1 clone 77.3D but not in 109.8C, encodes an enzyme with DNA glycosylase and DNA lyase activity and could be involved in DNA repair. NTLH1 is located 5′ to 3′, “head to head”, with the Tsc2 gene with only 63 bp in between. Furthermore, the gene is located in a 3′ to 3′, “tail to tail”, orientation with the SLC9A3R2 gene. This gene encodes the regulatory factor 2 of the solute carrier family 9 (sodium/hydrogen exchanger), but has recently been shown to be a regulator for phospholipase-β. The distal deletion breakpoint is not exactly known. One or both of the genes NTLH1 and SLC9A3R2 may be deleted or disrupted in the patient.

Exon trapping has previously identified four of the genes located in the 280 kb deletion interval, ABCA3, RNPS1, E4F1, and RAB26. The authors identified one additional transcript, “3′”, located between E4F1 and RAB26, with unknown function.

The SstD transducin gene, the human ERV1 gene, and the gene encoding the ribosomal protein-like 3 (RPL3L) are located distally from the deletion interval. The human somatostatin receptor 5 gene also maps outside the interval, on cosmids 349E16, although in the Puffer fish Fugu, the gene is located within 10 kb proximal of the Pkd1 gene.

### DISCUSSION

Tuberous sclerosis (TSC) is a genetically heterogeneous disorder with genes on chromosome 9 (TSC1) and chromosome 16 (TSC2). In the patient presented in this paper, the diagnosis of TSC was based on adena sebaceous, nail fibroma, and shagreen patches. Along with TSC, he had dysmorphic features, triphalangeal thumbs, and hearing loss, consistent with a diagnosis of acrofacial dysostosis. A patient with acrofacial dysostosis and a balanced translocation 46,X,t(X;9)(p22.1;q32) inherited from a mosaic carrier mother was described by Zori et al.
suggesting the location of a gene for acrofacial dysostosis on chromosome 9 or on the X chromosome. The fact that the TSC1 gene is located on chromosome 9q34 prompted us to analyse this chromosomal region, but no chromosomal aberration was found. As the patient also had polycystic kidneys, it was a logical step to analyse the short arm of chromosome 16, uncovering a microdeletion of approximately 280 kb. Since dysmorphic facial features are not manifestations of either TSC or ADPKD, we suggest that the region also harbours an acrofacial dysostosis gene. Database analysis showed at least six other genes in the deletion interval.

The acrofacial dysostoses are a heterogeneous group of disorders with craniofacial anomalies and defects in limb development. For a large number of malformation disorders, disruption or dosage effects of specific transcription factors or transcription enhancers/repressors are known to cause the disease. On this basis the ZFP-37 gene, a putative transcription factor belonging to the GLI-Kruppel gene family, was proposed as a candidate gene for the Nager acrofacial dysostosis syndrome. Interestingly, E4F1, deleted in our patient, is also a transcription factor related to the GLI-Kruppel family of zinc finger proteins. There have been reports of other deletions of patients with no dysmorphic phenotype, which partly overlap with the deletion described here. The most proximal extending deletion extends 80 to 100 kb proximal from exon 1 of the PKD1 gene, which is probably distal to E4F1. Recently, a patient with an unbalanced translocation t(8;16)(q24.3;p13.3) with TSC, ADPKD, and hypomelanosis of

Figure 2  Map of the PKD1-TSC2 region on chromosome 16p13.3. (A) The deletion of approximately 280 kb is indicated. Orientation of genes in the region is indicated with an arrow. The PAC clones are indicated below the line. (B) Fibre-FISH with clones 64.12C (red) and 77.3D (green) showing a fusion of the signals of these two clones. Separate signals of PACs on the normal chromosome are also shown. Note that because of the deletion they are not only fused, but also reduced in size.
Ito was described.\textsuperscript{2} Downward slanting palpebral fissures, mild malar hypoplasia, and mild retrogнатia were present in this patient, but acrodysostosis was not reported. In this patient, however, the most telomeric part of 16p is deleted, including the \textit{PKD1}, TSC2, and \textalpha-globin genes, and the \textit{8q24.3-qter} region is duplicated. The chromosome 16 breakpoint is located in P1 clone 1.8F but the position in relation to \textit{EAF2} is not known.

The distal deletion breakpoint is located in the middle of P1 77.3D. Two genes are located very close to the breakpoint, the endonuclease III-like 1 gene and the gene encoding the regulatory factor 2 of the solute carrier family 9 (sodium/hydrogen exchanger).\textsuperscript{16} As we did not observe reduced FISH signals for P1 109.8C, the breakpoint is located proximally to or at the beginning of this clone. The proximal breakpoint disrupts the ATP binding cassette transporter \textalpha-BC3. The substrate of the transporter is not known but the highest mRNA expression has been seen in lung tissue.\textsuperscript{17}

In general, deletions spanning \textit{TSC2} and \textit{PKD1} have been implicated in a severe and infantile form of polycystic kidney disease in TSC.\textsuperscript{18} Progression of renal cystic disease is apparently accelerated when, in addition to inactivation of the \textit{PKD1} gene, \textit{TSC2} function is lost. A patient with neonatal presentation of polycystic kidney disease with paternally inherited ADPKD and maternally inherited TSC supports this observation.

A few other \textit{TSC2-PKD1} deletion patients with a milder phenotype have been described.\textsuperscript{19,20} Sampson \textit{et al} observed somatic mosaicism in four of 22 patients with contiguous deletions of \textit{TSC2} and \textit{PKD1}. The relatively mild cyst phenotype found in our patient could be the result of somatic mosaicism. Alternatively, genes in the region countering the effect of the \textit{PKD1/TSC2} genes or modifying genes located on other chromosomes could explain the milder phenotype of the patient presented here. FISH analysis did not show any mosaicism in the patient presented in this paper, but this was only performed on EBV transformed lymphoblastoid cells. Unfortunately, the patient died from renal failure and inadequate compliance with haemodialysis. For this reason, a fresh blood or tissue sample to test for mosaicism could not be obtained. We therefore cannot definitively conclude whether the mild phenotype was caused by mosaicism or by other genes influencing the phenotype.

The \textit{PKD1-TSC2} region on chromosome 16p13 is particularly rich. We propose that haplinsufficiency of one of these genes can cause acrofacial dysostosis or that the deletion has exposed a mutation in a gene on the non-deleted chromosome. The transcription factor \textit{EAF1} seems to be an interesting candidate gene.

ACKNOWLEDGEMENTS

We thank G Landes (Genzyme Corporation, Framingham, USA) for the P1 clones. We also thank P Taschner for advice and assistance in database analysis, S White for critical reading of the manuscript, and the Dutch Kidney Foundation for financial support (C95-111).
Partial trisomy 9p12p21.3 with a normal phenotype

M Stumm, J Müsebeck, H Tönnies, M Volleth, J Lemke, I Chudoba, P Wieacker

Partial trisomy or tetrasomy of the short arm of chromosome 9 are among the most common autosomal structural chromosomal anomalies in humans, so the phenotype-genotype correlation of these aneusomies has been well described. Characteristic clinical features of partial trisomy 9p are mental retardation of various degree, short stature, craniofacial abnormalities, short fingers, simian crease, and single crease of the fifth finger. Additional symptoms like microcephaly, cleft lip and palate, malformed ears, and skeletal, nail, cardiac, and genital anomalies have also been observed. 

In 1970, the first case of trisomy 9p was reported by Réthoré et al. Since then, more than 150 patients with partial or complete trisomy 9p have been reported. In most patients, the trisomic segment was transmitted from a parent carrying a reciprocal balanced translocation and only a small number arose from de novo duplications.

Here we report on a three generation family with an interchromosomal insertion of chromosome 9p12-p21 material into the short arm of chromosome 5. One member of the family carried a deletion in the inserted region resulting in cri du chat syndrome, whereas her father is trisomic for the inserted segment owing to an unbalanced segregation of the insertion chromosome. Surprisingly, the unbalanced insertion carrier does not show any morphological or mental abnormalities. The normal phenotype suggests that not all partial trisomies 9p are associated with clinical abnormalities. In particular, the proximal part of the short arm of chromosome 9 seems to be less important for the trisomy 9p phenotype.

CASE REPORTS

The female patient, III.1 (fig 1), is the third child of a 27 year old mother and the first child of a 24 year old father. The pregnancy and delivery were uneventful, the birth weight was 2830 g (3rd-10th centile), and length 48 cm (~3rd centile). The infant had feeding problems and chromosome analysis was performed because of clinical features of cri du chat syndrome, such as microcephaly, a round face, downward slanting palpebral fissures, deep set ears, microgenia, and atypical crying. Cytogenetic analysis showed the karyotype 46,XX,del(5)(p?)ISH del(5)(p?)D5S23-.

Because about 15% of cri du chat syndrome cases arise from parental chromosomal aberrations including reciprocal balanced translocations and inversions, chromosome analyses were also performed in the mother (II.1) and the father (II.2) of the affected child. The mother had a normal karyotype 46,XY,del(5)ins(5;9)mat46,XX,del(5)(p?)D5S23-.

In 1994, a large TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease - a contiguous gene syndrome. Nat Genet 1994;8:328-32.


Figure 1: Truncated pedigree of the family, including the important data.
METHODS
Metaphase chromosomes from PHA stimulated peripheral blood lymphocytes of the proband, his daughter, his mother, and his brother were analysed by standard GTG banding procedures and by FISH techniques. Appropriate informed consent was obtained from the family members. FISH studies were performed using the probe D5S23 (ONCOR), which is localised in the cri du chat syndrome critical region in 5p15.2, and the chromosome painting probes Coatasome 5 dig (ONCOR) and chromosome paint 9 bio (AGS) according to the supplier’s protocol. CGH analysis was performed as previously described.4 Seven YAC clones from the short arm of chromosome 9p were selected from the website of the Molecular Cytogenetic and Positional Cloning Centre of the Max Planck Institute for Molecular Genetics (Berlin, Germany). YAC-FISH was performed as described by Stumm et al.5 Multicolour banding (mBand, Metasystems, Germany) analysis was carried out using seven region specific partial chromosome paints (RPCP) of chromosome 5, which were generated as described by Chudoba et al.6

RESULTS
Because the composition of the derivative chromosome 5 of II.2 could not be determined by GTG banding (fig 2), a whole chromosome painting (WCP) with a chromosome 5 specific probe was performed on metaphases of II.2. In the short arm of the derivative chromosome 5, a gap in the painting pattern was detected, indicating an insertion of chromosomal material from a non-homologous chromosome.

Comparative genomic hybridisation (CGH) was applied to identify the additional material inserted in the short arm of chromosome 5. CGH showed a gain of material in the proximal region of the short arm of chromosome 9 (rev ish enh(9)(p12p21)) (fig 3). A further WCP using a chromosome 9 specific probe confirmed the CGH result and detected an insertion of chromosome 9 material in the short arm of chromosome 5 (fig 4).

mBand and WCP analysis on metaphases of the cri du chat syndrome patient (III.1) with chromosome 5 and chromosome 9 specific probes showed that the breakpoint of the

Figure 2  GTG banded chromosomes 9 and 5 from a metaphase of II.2. Both chromosomes 9 and one chromosome 5 are normal. The der(5) harbours the unbalanced insertion of chromosomal bands (9)(p12p21.3).

Figure 3  CGH profiles of the proband’s (II.2) chromosomes. The thin vertical lines represent ratio profile value of 0.5 and 1.5. The average profile of chromosome 9 shows amplification of proximal 9p.

Figure 4  Partial metaphase of II.2 showing whole chromosome painting with a chromosome 9 specific probe. A chromosome 9 specific signal is visible in the short arm of chromosome 5.
depleted chromosome 5 occurred in the inserted region of the paternally inherited derivative chromosome 5. The chromosome 5 breakpoint could be determined by mBand at 5p13.3 (fig 5). Therefore, patient III.1 has a partial monosomy some 5 breakpoint could be determined by mBand at 5p13.3 (fig 5). The origin of the der(5) telomere remains unclear.

Chromosome analyses of the mother (I.2) and the brother (II.3) of II.2 showed a balanced insertion of material from the short arm of chromosome 9 into the short arm of chromosome 5 (ins(5;9)(p13.3;p12p21)). The GTG banding results were confirmed by FISH using chromosome 5 and chromosome 9 specific whole chromosome painting probes (fig 6).

For a better characterisation of the trisomic region, microsatellite analysis with seven markers from chromosome 9p and one marker from chromosome 9q was performed on DNA from I.2, II.2, II.3, and III.1. Most markers in the critical region were not informative. Only microsatellite marker D9S104 showed three different alleles in III.1, confirming a trisomy for the subband 9p21 (data not shown). Therefore, YAC-FISH was performed to determine the trisomic region in more detail.

According to the GTG banding and CGH results, the trisomic segment was postulated to include the chromosomal subbands 9p12-9p21.3. Five different YAC probes localised within and two YAC probes localised outside this region were hybridised to metaphases of II.2. All YACs from the critical region 9p12-p21.3 resulted in three specific signals, two on the normal chromosomes 9 and one on the derivative chromosome 5. In contrast, the YACs which are localised in 9p23 and 9p24 only showed signals on both chromosomes 9.

Taking all the cytogenetic results together, II.2 is a carrier of an unbalanced maternally inherited inserted translocation (5;9)(p13.3;p12p21.3) resulting in a partial trisomy 9p12-p21.3. This case shows the efficient use of CGH, WCP, and mBand for the correct identification of chromosomal material of unknown origin and of the mechanisms generating structural chromosome aberrations.

**DISCUSSION**

Chromosomal insertions, with an estimated frequency of less than 1 in 5000 newborns, are relatively rare chromosome rearrangements. Only a few reports of inherited interchromosomal insertions have been published and most cases have arisen de novo. Insertions may lead to disruption of genes, position effects with alterations of gene function, or loss of acquisition of chromosomal segments that cannot be detected by cytogenetic methods. Unbalanced transmission of insertion chromosomes results in partial trisomies and/or monosomies. We report on an unbalanced inherited maternal insertion (5;9)(p13.3;p12p21.3) resulting in partial trisomy 9p12-p21.3. To the best of our knowledge, this is the first report of partial trisomy 9p and a normal phenotype. The normal phenotype is unexpected, because the unbalanced insertion includes a trisomic segment of about 21 Mb (Entrez Map View Chromosome 9, Genes on Sequence Map), harbouring about 280 genes (Entrez Map View Chromosome 9, Genes on Cytogenetic Map). It is usual that such large autosomal trisomies result in mental retardation and morphological anomalies. In particular, partial trisomy 9p is a well described phenotype and results in a complex clinical malformation pattern. Haddad et al. reviewed the phenotypic effects of different trisomic regions of chromosome 9p. They compared the phenotypic and clinical findings of 144 previously published cases with partial or complete trisomy 9p. The majority of these cases were caused by an unbalanced translocation involving another chromosome. Phenotypic effects of these additional segments could not be excluded in these cases. Therefore, the authors confined their analysis to 11 patients with direct duplications of 9p. There was a remarkable consistency in the facial and digital anomalies, which were present in all patients. A general trend towards a milder phenotype in cases with smaller and more distal duplications could be suspected. Furthermore, the characteristic trisomy 9p phenotype showed the best correlation with the 9p22 region. FISH analyses by Fujimoto et al. and Guanciali Franchi et al. suggest that the segment 9p22 may be the critical region for the duplication 9p syndrome. Band 9p22

---

**Table 1** Results of the YAC-FISH with probes spanning the chromosomal region 9p12 to 9p24

<table>
<thead>
<tr>
<th>YAC</th>
<th>Localisation*</th>
<th>Chr 9 (1)</th>
<th>Chr 9 (2)</th>
<th>ins(5;9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>961e04</td>
<td>9p23-24</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>833e12</td>
<td>9p23</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>942f10</td>
<td>9p21-22</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>785f08</td>
<td>9p13-21</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>854e10</td>
<td>9p13</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>926e09</td>
<td>9p13</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>902g06</td>
<td>9p12</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

* Database information from the website of the MPI in Berlin.
was shown to be duplicated in all patients with de novo duplications of 9p without involvement of another chromosome abnormality. Just one patient\(^7\) showed a duplication without involvement of 9p22. Very limited information is available on this patient and the precise breakpoint must be questioned because chromosome analysis was performed at a low banding level.\(^7\) These findings could also explain why our proband showed no phenotypic abnormalities, because the “critical” region 9p22-9p24 does not seem to be involved in the partial trisomy 9. However, the normal phenotype in II.2 suggests that the genes located in the trisomic segment may not be subject to dosage effect.

A further case with a combination of cri du chat syndrome and partial trisomy 9p was described by Sigmund et al.\(^11\) In this case, the combination resulted from an unbalanced translocation (5;9)(p13.3;p13.1). The patient harboured the “critical” segment 9p22 and showed typical clinical features of both chromosomal abnormalities.

Impacting effects may also be an explanation for the unexpected phenotype in our patient. However, clear imprinted regions on chromosome 9 have not been confirmed so far (Imprinted Gene Catalogue Records, 2000).

It is difficult to estimate the reproductive risk for further children of II.2, because he has an interchromosomal duplication resulting from an unbalanced inherited maternal insertion. Insertions can be associated with a very high reproductive risk. The average risk of insertion carriers to have a child with an abnormal phenotype is in the range of 10-50%. Two possibilities of segregation in meiosis have to be considered in our case. Firstly, the risk for the transmission of the rearranged chromosome 5 in II.2 is a priori 50%, which is higher than the risk for a straightforward insertion. However, the risk for an abnormal phenotype must be lower, because II.2 has a normal phenotype. Secondly, there is also a risk for a deletion in 5p, which can be best explained by a synapsing of the homologous chromosomes 5 in meiosis I, followed by a loopout of the insertional segment and a break inside the loop.\(^6\) However, this deletion risk is difficult to estimate and no specific published data are available. All in all, a detailed risk estimation cannot be given in the present case, but a prenatal diagnosis should be performed in further pregnancies of II.2, as well as of his brother.

For further analysis of the unexpected genotype-phenotype correlation of patient II.2, we have established a lymphoblastoid cell line of this patient. Expression analysis by array technologies may show whether the trisomic segment alters the gene expression profile in these cells.

ACKNOWLEDGEMENTS

The authors thank Mrs R Drange, Mrs B Bütow, and Mrs B Plickthun for excellent technical assistance. We also thank Dr J Wirth from the Molecular Cytogenetic and Positional Cloning Centre of the MPI of Molecular Genetics in Berlin for providing VAC-DNA and Mrs K Saar from the Microsatellite Centre of the Max-Delbrück-Zentrum in Berlin for performing microsatellite analysis. Furthermore, we thank Metasystems for paying for the colour figures.


REFERENCES

Neural tube defects are usually multifactorial. They can also be associated with a number of underlying monogenic or chromosomal conditions. These include autosomal recessive disorders, such as Meckel-Gruber, Roberts, and Walker-Warburg syndromes, and chromosomal anomalies, such as microdeletion 22q11.\(^1\) Also, teratogenic conditions, such as valproate embryopathy, may also have an association with neural tube defects.\(^1\) We present an apparently autosomal recessive, syndromic form of sacral neural tube defects resulting in tethered cord in two female sibs.

**CASE REPORTS**

Patient 1 was born to a G4, P3 mother and has three healthy, older maternal half sibs who have a different father. Her parents are of mixed European descent and non-consanguineous. The pregnancy history was negative for maternal illness or known teratogen exposure. Labour began spontaneously at 38 weeks. The delivery was complicated by fetal bradycardia following artificial rupture of the membranes. An emergency caesarian section was performed because of abruptio placentae. The birth weight was 1750 g (<3rd centile), head circumference was 30.5 cm (<3rd centile), and length 45.5 cm (<3rd centile). Apgar scores were 3 at one minute and 8 at five minutes. Two vessels were present in the umbilical cord. The placenta was found to have areas of calcification with a few foci of intravillous thrombosis and mild acute chorioamnionitis.

Atrial and ventricular septal defects, detected in infancy, were repaired at 10 months. A sacral dimple prompted an MRI of the spine which showed a low lying conus medullaris at the lower aspect of L2 (fig 1). The patient’s tethered cord was surgically repaired at 30 months. The patient has required a fundoplication and is fed by gastrostomy tube. She has also had surgical release of her heel cords and the tendons behind her knees.

She had her first ophthalmological examination at our institution at 18 months of age. Two weeks before this examination she had a left nasolacrimal duct probing at another institution for presumed obstruction. No external lacrimal system anomalies were present. At our initial examination, she showed normal visual responses for her age, clear lenses, and a normal eye examination with the exception of moderate, bilateral, symmetrical hyperopia (+5.00 sphere OU) for which spectacles were prescribed. By 23 months of age, she had developed a small accommodative esotropia that was well controlled with her hyperopic spectacles. At 30 months, her eye examination was once again normal. However, two months later her mother noted a white abnormality in the retinas. At the time of presentation with cataracts, it was difficult to view the retina although there was an impression of possible optic atrophy. Postoperatively, she has been noted to have mild retinal vessel tortuosity and bilateral temporal pallor of each optic nerve. She subsequently developed bilateral aphakic glaucoma that is controlled medically.

In view of the rapid onset of the cataract, a laboratory evaluation was undertaken. Sodium, potassium, chloride, calcium, creatinine, cholesterol, thyroid function studies, serum and urine amino acids, urine reducing substances, and serum lactate levels were all normal. MRI of the brain, chromosomes, FISH for microdeletion 22q11, very long chain fatty acids, uric acid, organic acids and oligosaccharides, mucopolysaccharide screen, and carbohydrate deficient glycoprotein testing have been normal. Subtelomeric FISH and SKY were later performed to search for cryptic chromosomal rearrangements and the results were normal.

A spine x-ray at 5 years of age showed multiple compression deformities of the spine resulting in thoracolumbar dextroscoliosis, thoracic kyphosis, and lumbar lordosis. Generalised decreased bone density and borderline delayed bone age were also noted. Her growth has continued to be delayed. At 8.6 years, her height was 97 cm (<3rd centile), weight was 16.8 kg (<3rd centile), and head circumference 46.5 cm (<3rd centile). She has a low anterior hairline with widow’s peak, persistent drooling, and a short philtrum with full lips (fig 2A, B). She has a geographic tongue with white lines. Her central incisors are prominent and widely spaced (fig 2C). She has micrognathia. Her ears are small but similar to her mother’s. Her chest is barrel shaped and prominent. She has bilateral inverted nipples. She has thoracic kyphosis, with some lordosis, mild scoliosis and mild gibbus. The veins in the shoulder region are prominent. Longitudinal grooves were noted on both the fingernails and the toenails. There was no limitation of movement of the upper limbs and hands. There was limitation of movement of both knees but this may be secondary to her neurological abnormalities. She has central hypotonia with peripheral hypertonia. This patient has remained preambulatory and preverbal. At the age of 8, she was recognised to be having seizures by EEG and was started on carbamazepine.

Patient 2, the younger sib of patient 1, was noted to have normal fetal growth on ultrasound at 20.9 weeks’ gestation. However, by 33 weeks’ gestation the fetus was noted to be small for gestational age. The placenta was noted on ultrasound to have prominent venous lakes and possible degenerative changes. Amniotic fluid volume was mildly increased. The baby was born at 36 weeks’ gestation with a birth weight of 1800 g (<3rd centile). A percutaneous gastric tube was placed because of a gastric septal defect with patent foramen ovale was diagnosed in infancy, but subsequently closed spontaneously. A tethered cord was repaired at 13 months of age.

Her first eye examination at our centre at 13 months of age showed clear lenses. She had mild hyperopia (+2.00 diopters).

**Abbreviations:** MCA/MR, multiple congenital anomalies/mental retardation
childhood, and growth and developmental retardation (table 1). Defects, sacral neural tube defects, cataracts developing in early life, characteristic craniofacial appearance, atrial ventricular septal heart defects, and chronic bilateral blepharitis. She has also developed bilateral aphakic glaucoma which is controlled medically.

At 3 years of age, she shows good corrected visual function in both eyes with an alternating exotropia of 20-25 prism dioptrons and chronic bilateral blepharitis. She has also developed bilateral aphakic glaucoma which is controlled medically. Her serum lactate was normal. A spine x ray at 2 years of age showed mild, generalised decreased bone density and borderline delayed bone age. Chromosomes, FISH for microdeletion 22q11, very long chain fatty acids, urine organic acids and oligosaccharides, mucopolysaccharide screen, and carbohydrate deficient glycoprotein testing have all been normal. Subtelomeric FISH and SKY were normal.

Like her sister, her growth has remained delayed. At 6 years of age, her weight was 16.4 kg (3rd centile), length was 95 cm (<3rd centile), and head circumference was 46.5 cm (<3rd centile). Her facies are similar to her older sister (fig 2D, E). She has central hypotonia with peripheral hypertonia. She has a low frontal hairline with a widow’s peak. Her eyebrows are broad, but have sparse hair. Her philtrum is short and she has prominent, widely spaced central incisors. She has micrognathia. Her ears are small. She has stiff joints in her upper limbs and hands. In her lower limbs, there is limitation in the movement of her knees. Her nails are normal. Examination of her genitalia showed pubic hair. Unlike her sib, this patient was almost walking by the age of 2 years. Unfortunately, she had a near drowning bathtub accident that aggravated her neurodevelopmental injury and she never regained this ability. Like her sister, she cannot talk. Following the accident, this patient developed seizures that are controlled medically.

**DISCUSSION**

The hallmark manifestations in this family include a characteristic craniofacial appearance, atrial ventricular septal heart defects, sacral neural tube defects, cataracts developing in early childhood, and growth and developmental retardation (table 1).

The unusual constellation of findings suggests to us that these sisters share a single genetic aetiology with early onset indicated by the presence of malformations occurring in embryogenesis, cardiac and neural tube defects. Perhaps the continued growth and developmental retardation and the onset of cataracts in early childhood would suggest an ongoing metabolic effect as part of this syndrome. In the absence of cryptic chromosomal rearrangements, this disorder is probably inherited in an autosomal recessive manner.

**ACKNOWLEDGEMENTS**

We thank the family for their cooperation. We also thank Rozmin Visram for her secretarial assistance.
Figure 2  [A, B, C] Patient 1. Whole body and close up of face and mouth. Note the broad central incisors. [D, E] Patient 2. Whole body and close up of face. Note the remarkable similarity to patient 1.
Dysmorphism, variable overgrowth, normal bone age, and severe developmental delay: a "Sotos-like" syndrome?

J Amiel, L Faivre, L Wilson, M Le Merrer, A Munnich, R Winter, S Lyonnet, V Cormier-Daire

Sotos syndrome (MIM 117550) is an overgrowth syndrome first described by Sotos et al. in 1964 with over 200 cases reported to date. The syndrome is characterised by prenatal and postnatal overgrowth, macrocephaly, advanced bone age, and distinctive facial features. In a review of 79 patients diagnosed as Sotos syndrome, Cole and Hughes showed that the overall gestalt was as efficient as clinical and radiological criteria for the diagnosis. The vast majority of cases are sporadic.

Concordant and discordant monozygotic twins have been reported. In rare instances, familial cases with autosomal dominant or autosomal recessive inheritance have been suspected and chromosomal rearrangements have also been reported. However, the aetiology of Sotos syndrome remains unknown. A hypothalamic origin was first suspected but extensive endocrinological testing failed to show significant anomalies. More recently, chromosomal uniparental disomy has been
ruled out.' Here, we report on five unrelated cases with a Sotos facial gestalt, severe developmental delay, moderate to absent overgrowth, and normal bone age. We propose a separate Sotos-like syndrome.

CASE REPORTS

Case 1

Case 1, a male, was the third child of healthy, non-consanguineous parents, aged 31 and 33 years at the time of birth. The mother's height was 1.57 m (25th centile) and the father's 1.72 m (between the 25th and 50th centile). Amniocentesi s was performed for at risk maternal serum screening and fetal chromosomes were normal 46,XY. Bilateral vesicoureteral reflux was diagnosed prenatally and surgically repaired at 9 months of age. He was born at term with normal birth parameters (birth weight 3360 g, 25th centile; length 51 cm, 50th centile). He had hypotonia and psychomotor delay (sat at 12 months, walked at 24 months, no words at 2 years). He was first investigated at 9 months; hypsarrythmia was diagnosed and treated with Vigabatrin. He was admitted to hospital eight days later with Streptococcus pneumoniae meningitis. When first seen, at 22 months of age, growth was in the normal range (weight 14 kg, 75th centile; height 90 cm, 75th centile; OFC 50.5 cm, 75th centile). Facial features included a long face with pointed chin, dolichocephaly, a high forehead with receding frontal hairline, fine hair, mild hypertelorism, epicanthic folds, and convergent strabismus. (B) Note dolichocephaly. (C) Note large feet and flat, brittle, deep set nails. (D) Note large hands and loose skin. The hands and feet were large with flat, brittle, deep set nails (fig 1C, D). Examination of the skin showed loose skin on the extremities and two punctiform scars across one arm. He stands with kyphosis, bent knees, and pes planus. Peripheral reflexes were brisk. Fundi were normal.

EEG showed hypsarrythmia and MRI of the brain showed a right parietofrontal cavity, a cyst of the septum pellucidum, and mild ventriculomegaly. At 22 months of age, bone age was 2 years for carpal bones, phalanges, and metacarpals according to Greulich and Pyle. Supernumerary epiphyses were present at the base of the second and third metacarpals. High resolution chromosomes were normal (46,XY) on lymphocytes with no fragile site on the X chromosome.

Case 2

Case 2, a male, was the third child of healthy, non-consanguineous parents aged 38 and 43 years at the time of birth. The mother's height was 1.70 m (90th centile) and the father's 1.87 m (>97th centile). The mother's OFC was 57 cm (97th centile). The older brother's and sister's heights were above the 97th centile (1.81 m at 14 years and 1.78 m at 13 years, respectively). Amniocentesis for maternal age showed normal fetal chromosomes, 46,XY. The mother had hypertension in the third trimester of the pregnancy. He was born at term with normal birth parameters (birth weight 3570 g, 75th centile; length 54 cm, 90th centile; OFC 36.5 cm, 75th centile). There was a unilateral cleft lip and upper gum, feeding difficulties, hypotonia, hyperbilirubinemia, and hypoglycaemia at birth. He showed psychomotor delay (sat at 12 months, walked at 24 months, no words at 6 years). When first seen, at 26 months of age, growth was above the mean (weight 16 kg, 90th centile; length 100 cm, 97th centile; OFC 54.5 cm, >97th centile). Facial features included a long face with pointed chin, dolichocephaly, a high forehead with receding frontal hairline, fine hair, mild hypertelorism, epicanthic folds, and downward slanting palpebral fissures (fig 1A, B). The hands and feet were large with flat, brittle, deep set nails (fig 1C, D). The skin was velvety. He stands with kyphosis, bent hips and knees, and pes planus. Fundi were normal. At 6 years of age, height is above the 97th centile, weight is between the 90th and 97th centile, and OFC is above the 97th centile.

MRI of the brain showed mild ventriculomegaly. At 26 months of age, bone age was 2 years 8 months according to Greulich and Pyle. Pseudoepiphyses were present at the base of the second and fifth metacarpals. High resolution chromosomes were normal (46,XY) on lymphocytes with no fragile site on the X chromosome. Auditory evoked potentials and abdominal ultrasound were normal.

Case 3

Case 3, a male, was the first child of healthy, non-consanguineous parents aged 28 and 42 years at the time of birth. The mother subsequently had two miscarriages. The mother's height was 1.60 m (50th centile) and the father's 1.72 m (25th centile). Case 3 was born at 33 weeks of gestation (birth weight 2100 g, 50th centile; length 44 cm, 50th centile; OFC 32 cm). He had ventricular septal defect and a patent ductus arteriosus that closed spontaneously. Psychomotor development was delayed (sat at 14 months, walked at 3 years, three words at 2 years 10 months). At 11.5 years of age, height and weight were on the 97th centile and OFC >97th centile.

Letters

Figure 1 Case 1. (A) Note the long face with pointed chin, high forehead with receding frontal hairline, fine hair, mild hypertelorism, and convergent strabismus. (B) Note dolichocephaly. (C) Note large feet and flat, brittle, deep set nails. (D) Note large hands and loose skin.
He attended normal school with two years delay. Facial dysmorphic features included a long face with a pointed chin, a high forehead with receding frontal hair line and fine hair (fig 3A, B). The hands and feet were large (>97th centile) with flat, deep set nails that required surgery.

Brain CT scan showed mild ventriculomegaly. At 3 years of age, bone age is 3 years 6 months according to Greulich and Pyle. High resolution chromosomes were normal (46,XX) in lymphocytes. Fragile X was ruled out by molecular testing.

Case 4
Case 4, a female, was the first of two children of healthy, non-consanguineous parents aged 30 and 22 years at the time of birth. The mother's height was 1.53 m (10th centile) and the father's 1.74 m (50th centile). The mother had two healthy children from a previous union. She was born at term after an uneventful pregnancy with birth parameters as follows: birth weight 3140 g, 50th centile; OFC 36.5 cm, 90th centile (length not recorded). Psychomotor development was slow and she was hyperactive with temper tantrums and obsessional behaviour (sat at 9 months, walked at 18 months, no words at 3 years 10 months). Seizures occurred at 7 months of age and were treated by carbamazepine. Patent ductus arteriosus was surgically repaired at 1 year. Growth followed the 50th centile until the age of 3.5 years. Growth acceleration started at that age with height on the 90th centile; weight and OFC were above the 97th centile at 5 years of age. Facial dysmorphic features included a long face with a pointed chin, a high forehead, dolichocephaly, hypertelorism, epicanthic folds, downward slanting palpebral fissures, strabismus, a low nasal bridge, and a narrow, high palate (fig 3C, D). Extremities were large with bilateral 2-3 syndactyly of the toes. Examination of the skin was normal.

A brain CT scan and MRI showed mild ventriculomegaly. Electroencephalography was normal. At 3 years 10 months of age, bone age was between 2 years and 3 years 8 months according to Greulich and Pyle. Blood karyotype showed normal chromosomes (46,XX) in lymphocytes. Fragile X was ruled out by molecular testing.

Case 5
Case 5, a male, was the second child of healthy, unrelated parents. Both parents were of average stature but their heights were 1.53 m (10th centile) and 1.74 m (50th centile). Psychomotor development was slow and he was hyperactive with temper tantrums and obsessional behaviour (sat at 9 months, walked at 18 months, no words at 3 years 10 months). Seizures occurred at 7 months of age and were treated by carbamazepine. Growth followed the 50th centile until the age of 3.5 years. Growth acceleration started at that age with height on the 90th centile; weight and OFC were above the 97th centile at 5 years of age. Facial dysmorphic features included a long face with a pointed chin, a high forehead, dolichocephaly, hypertelorism, epicanthic folds, downward slanting palpebral fissures, strabismus, a low nasal bridge, and a narrow, high palate (fig 3C, D). Extremities were large with bilateral 2-3 syndactyly of the toes. Examination of the skin was normal.
were not recorded. He was born at term with a normal birth weight (3300 g). At 21 months of age, growth was in the normal range (weight 12.9 kg, 75th centile; height 86.4 cm, 75th centile; OFC 52.1 cm, 97th centile). Psychomotor development was delayed (standing with support, one word). Facial dysmorphic features included dolichocephaly, a high forehead with frontal bossing and receding frontal hair line, a long face with a pointed chin, downward slanting palpebral fissures, strabismus, a high palate, and a unilateral ear pit. He had large hands and feet. The skin was lax and he had three café au lait patches.

Brain CT scan showed partial agenesis of the corpus callosum. Blood karyotype showed normal chromosomes (46,XY) on lymphocytes and fragile X was ruled out by molecular testing. At 21 months of age, bone age was 2 years 8 months according to Greulich and Pyle while his distal radial epiphysis was not yet visible.

**DISCUSSION**

Here we report five unrelated patients with the combination of similar and distinctive facial features, loose skin on the extremities with brittle, deep set nails (3/5), moderate to severe developmental delay, moderate to absent overgrowth, normal bone age, and mild ventriculomegaly (tables 1 and 2). The five cases we report are sporadic and no consanguinity was observed. There was no known exposure to drugs or toxins during the pregnancies. Fragile X syndrome was ruled out

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical and radiological findings in the five reported cases and four published cases discussed as “Sotos-like” syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Case 1</td>
</tr>
<tr>
<td>Parental height (centile)</td>
<td>M</td>
</tr>
<tr>
<td>(mother/father) 25th / 25th–50th</td>
<td>90th/</td>
</tr>
<tr>
<td>Growth parameters</td>
<td>Weight</td>
</tr>
<tr>
<td>Height</td>
<td>90th</td>
</tr>
<tr>
<td>OFC</td>
<td>50th</td>
</tr>
<tr>
<td>Growth parameters</td>
<td>Weight</td>
</tr>
<tr>
<td>Height</td>
<td>75th</td>
</tr>
<tr>
<td>OFC</td>
<td>90th</td>
</tr>
<tr>
<td>Delayed psychomotor development</td>
<td>+</td>
</tr>
<tr>
<td>Sotos gestalt</td>
<td>+</td>
</tr>
<tr>
<td>Bone age*</td>
<td>Normal</td>
</tr>
<tr>
<td>Karyotype</td>
<td>46,XY</td>
</tr>
</tbody>
</table>

*According to Greulich and Pyle.

Suzuki et al. | Robertson and Bankier** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>Case 2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Facial dysmorphic features in the five reported cases and four published cases compared to distinctive facial features in a series of patients with Sotos syndrome*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facial features</td>
<td>Case 1</td>
</tr>
<tr>
<td>Sotos syndrome*</td>
<td>97.5%</td>
</tr>
<tr>
<td>High forehead</td>
<td>97.5%</td>
</tr>
<tr>
<td>Prominent jaw</td>
<td>95%</td>
</tr>
<tr>
<td>Downward slanting palpebral fissures</td>
<td>90%</td>
</tr>
<tr>
<td>Facial flushing</td>
<td>85%</td>
</tr>
<tr>
<td>Dolichocephaly</td>
<td>80%</td>
</tr>
<tr>
<td>High palate</td>
<td>70%</td>
</tr>
</tbody>
</table>

*From Cole and Hughes.3

CL, cleft lip.

UCLP, unilateral cleft lip and palate; PDA, patent ductus arteriosus; CC, corpus callosum.
in all patients and there was no identified chromosomal rearrangement on blood karyotyping.

Features consistently observed in our patients have been described in Sotos syndrome, namely facial gestalt, large extremities, brittle, deep set nails, and loose skin. Similarly, mild, non-specific ventriculomegaly and corpus callosum agenesis are frequently found in Sotos syndrome. Therefore, although the five patients have the Sotos syndrome facial gestalt, they share features that make Sotos syndrome unlikely, namely absence of overgrowth and macrocephaly at birth, growth acceleration of late onset that remained moderate (from 26 months to 6 years of age, patients 2-4), normal bone age, and severe psychomotor delay. Macrocephaly-cutis marmorata telangiectatica congenita syndrome was considered in case 4 and ruled out because of absent overgrowth and macrocephaly at birth, absence of segmental overgrowth and hydrocephalus, and normal skin examination. Finally, none of the syndromes included in the differential diagnosis of Sotos syndrome seem satisfactory, namely Weaver-Smith (MIM 277590), autosomal dominant macrocephaly (MIM 153470), and Zonana-Bannayan (MIM 153480) syndromes.

Sotos syndrome remains of unknown aetiology and may have been overdiagnosed. Reviewing published reports, we found four cases which may be similar to the cases reported here. Suzuki et al.10 reported a male patient diagnosed as Sotos syndrome who showed the combination of increased height, large extremities, normocephaly, hypsarrhythmia, and moderately advanced bone age (table 1). Because of the ethnic origin, dysmorphic features are difficult to appreciate. Nevertheless, the patient showed a high forehead with receding frontal hair line, downward slanting palpebral fissures, and a high arched palate (table 2). Robertson and Bankier11 reported three unrelated cases with the combination of an overall Sotos gestalt, macrocephaly, moderate to absent overgrowth, developmental delay, and normal bone age (tables 1 and 2). They put emphasis on symptoms suggestive of a connective tissue disorder, namely cutis laxa, joint hypermobility, and vescicoureteric reflux. Cole and Hughes12 reviewed 79 cases diagnosed as Sotos syndrome and categorised 22 patients as “definitely not Sotos” (28%). Among this group, two sisters were described as combining “significant developmental delay and characteristic faces with normal bone age and chromosomal analyses”. They may represent the Sotos-like syndrome. Goldstein et al.12 reported two unrelated patients with overgrowth, macrocephaly, advanced bone age, developmental delay, nystagmus, and dysmorphic facial features with epicanthic folds, a depressed nasal bridge, and antverted nares. The authors raised the question of a variant of Sotos syndrome. We believe that they represent a distinct entity from the cases we report.

In the absence of definitive genetic tests, one should be cautious with the diagnosis of Sotos syndrome. We propose a Sotos-like syndrome for the association of Sotos facial gestalt, moderate overgrowth and macrocephaly, severe development delay, and normal bone age. We do not know whether the Sotos-like syndrome is allelic to Sotos syndrome or genetically distinct if of genetic origin, the cases we report being sporadic. It would be of interest to know whether other clinicians have encountered similar patients and experienced the same diagnostic difficulties.

ACKNOWLEDGMENTS

We thank the families for their cooperation and Professor Brunelle for reviewing the patients’ x-rays and for helpful discussion.

References

Unique de novo mutation of BRCA2 in a woman with early onset breast cancer

M Robson, L Scheuer, K Nafa, N Ellis and K Offit

doi: 10.1136/jmg.39.2.126

Updated information and services can be found at:
http://jmg.bmj.com/content/39/2/126

These include:

References
This article cites 10 articles, 4 of which you can access for free at:
http://jmg.bmj.com/content/39/2/126#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Breast cancer (239)
Screening (oncology) (234)
Clinical diagnostic tests (356)
Epidemiology (630)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/